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At-risk drinking is defined as drinking above the recommended limits, which is no more than 
four drinks (one drink contains 14 grams of pure alcohol) in one day for men (three for women) and 
no more than 14 drinks in one week for men (seven for women). At-risk drinking is associated with 
adverse health outcomes in the general population. For persons with HIV (PHIV), they may have 
increased risk for developing adverse outcomes even at lower levels of consumption such as 
increased risk of liver damage, more rapid virus growth, increased risk of depression, decreased 
medication adherence, and increased engagement in high risk sexual behaviors, resulting in the 
possibility of reinfection with HIV or other sexually transmitted infections (STIs). What’s worse, the 
use of alcohol in PHIV is a concern not only for younger adults but also for those in older cohorts. 
However, there are lack of studies on how alcohol use affects health outcomes exclusively targeting 
PHIV with advanced age. This is especially concerning because with the development of 
antiretroviral therapy (ART), the number of aged PHIV is growing. In the first manuscript, a 
systematic review as conducted to evaluate existing studies on the association between alcohol use 
and medication adherence, engagement in high risk sex behaviors, resource utilization, HIV 
progression, depression, and survival in studies that included PHIV with an average age 40 and 
above. 
Anxiety is prevalent among PHIV, especially among women with HIV (WHIV). It may have 
both direct and indirect effects on HIV/AIDS progression. Although the relationship between alcohol 
use and depression has been extensively examined, studies on alcohol use and anxiety among PHIV 
are limited. Thus, in the second manuscript, I examined the association between changes in 
generalized anxiety and changes in alcohol use among WHIV over a period of 12 months.  
Engagement in health care system for clinical appointments and treatment, is one step in the 
HIV Care Continuum that is important for PHIV to suppress viral load and decrease mortality. 
Unfortunately, a significant proportion of PHIV have poor engagement in HIV care. Although there 
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are extensive literature demonstrating the negative relationship between mental health symptoms and 
medication adherence, there have not been much studies examining mental health symptoms and 
likelihood of attending primary care visits among PHIV, especially WHIV. Thus, in the third 
manuscript, I examined the impact of baseline alcohol use, anxiety, and depression on likelihood of 
attending primary care visits among WLHV.  
Data of the second and third manuscript came from two concurrently recruited cohorts of 
WHIV. One was a randomized controlled trial (RCT) designed to test the effectiveness of a brief 
alcohol intervention (BI) among WHIV with baseline at-risk drinking (defined as 8 or more 
drinks/week, 2 or more binge drinking episodes [defined as 4 or more drinks/occasion] in the past six 
months, or TWEAK score ≥2). The TWEAK alcohol screening consists of five-questions with a total 
score of 7 points (the first two questions counts for 2 points each, other questions worth 1 point). A 
total score ≥2 indicates at-risk drinking. The second cohort was a concurrently recruited sample of 
WHIV without at-risk drinking at baseline from the same clinic. The parent studies were registered at 
clinicaltrials.gov: NCT00127231 and were approved by the Johns Hopkins Medicine Institutional 
Review Board. 
Participants were recruited between March 2006 and September 2010 through several 
methods, including clinic flyers, provider referral, waiting room recruitment, and review of drinking 
data obtained from an audio-computer-assisted-self-interview (ACASI) routinely administered to 
patients who have consented to enroll in the HIV Clinical Cohort every six months. Parent studies 
inclusion criteria included women who 1) had a confirmed HIV infection; 2) received outpatient care 
at the Johns Hopkins HIV Clinic; 3) were 18 years of age or older; 4) were not receiving treatment 
for an alcohol use disorder (AUD); 5) not pregnant; and 6) had no history of psychosis at the time of 
enrollment. Women in the RCT had visits at baseline and three, six, and twelve months post-
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I grew up in China and was used to develop a stereotypical opinion of the nursing field. 
Through my observations in Chinese hospitals, most nurses are educated at an associate or even high 
school level and follow physicians’ orders in a non-creative and non-autonomic manner. It seems that 
research and policy innovations are not tangible in this profession. However, after two years of BSN 
study at Emory, I gained a more profound understanding of nursing research. For every practice, I 
observed in the clinical setting, I found research strongly connected to improving practices to yield 
the best patient outcome. Nursing research now more than ever urges my generation to devote our 
diligence, intelligence, passion, and creativity to addressing the emerging issues regarding equal 
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access to healthcare, chronic disease prevention and management, and the aging population. Thus, I 
determined to seek a nursing PhD study at my very early career.  
After getting the offer from Johns Hopkins, I could not be more excited because I could never 
think or even dream about this offer before. I am also very grateful that the school offers fellowship 
that relieved financial burden for me and my family for my study. Three years’ study seemed 
transient as I even vividly remembered the first day of school, full of curiosity and innocence. What I 
learned most during the past three years is that 1). Doing research is a life-long learning process. I 
should never expect to reply on existing knowledge to conquer the challenges I encounter now and in 
the future. I should constantly update my knowledge base and skill sets. 2). Doing research requires 
us to turn frustration into motivation. Only when we feel frustrated can we realize our limitations and 
make process. During the past three years, I often, if not always feel frustrated with myself and 
gradually learn to live with it and live with it in peace. Upon graduation, I only sense a need to 
further develop my research skills rather than feel accomplished. 3). Doing research requires strong 
teamwork and guidance. The great mentors I encountered really help me get into research, not only 
about how to choose a proper statistical method and how to write a manuscript but how to come up 
with a research question, how to think about an issue thoroughly, and work on it in a team. I really 
appreciate their efforts and patience with me. I know I am often thinking from the perspective of a 
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Alcohol use is prevalent among women with human immunodeficiency virus (WHIV). Among 
1123 WHIV in the Women's Interagency HIV Study (WIHS), 62% reported current alcohol use and 
7% reported heavy use (Kelso-Chichetto et al., 2017). At-risk alcohol use among women, defined as 
≥4 standard drinks (one standard drink contains 14 grams of pure alcohol (National Institute on 
Alcohol Abuse and Alcoholism, 2016)) per occasion, or average daily drinking of >1 drink, interferes 
with entry and retention in the HIV care continuum (Kay, Batey, & Mugavero, 2016)-the steps that 
persons with HIV (PHIV) progress through in order to achieve and maintain viral suppression 
(Braithwaite & Bryant, 2010; Braithwaite et al., 2005; Erickson, Becker, Shaw, Kasper, & Keynan, 
2015; Etienne, Hossain, Redfield, Stafford, & Amoroso, 2010; Fatch et al., 2013; Gordon et al., 
2006; Kelso-Chichetto et al., 2017; S. Lee et al., 2016; Monroe et al., 2016a). These steps include 
linkage and retention in care, antiretroviral receipt and adherence, and viral suppression. Thus, at-risk 
drinking may increase the risk of developing adverse health outcomes among PHIV. This problem 
may be further compounded among WHIV since women are biologically more vulnerable to the 
effects of alcohol (Cole-Harding & Wilson, 1987; Frezza et al., 1990) and are more likely to delay 
alcohol treatment compared with men (Green, Freeborn, & Polen, 2001).  
 
Anxiety 
Anxiety is more prevalent among women compared with men in the general population and 
among WHIV compared with un-infected women (Chander & McCaul, 2003; McLean, Asnaani, 
Litz, & Hofmann, 2011; Saadat, Behboodi, & Saadat, 2015; van den Heuvel et al., 2013). This is 
associated with the fact that living with HIV can be a difficult experience and is associated with onset 
of comorbid mental disorders (Saadat et al., 2015). For example, HIV-related experiences such as a 
recent diagnosis of HIV (M.-K. Kee et al., 2015) and greater HIV-related stigma (Kamen et al., 
2015) have been associated with increased symptoms of anxiety and emotional distress among PHIV. 
Demographic factors, drug use, and social support are also important predictors of anxiety among 
PHIV (Catz, Gore-Felton, & McClure, 2002; M. K. Kee et al., 2015). Anxiety may also have both 
direct and indirect negative effects on HIV/AIDS progression (Chander, Himelhoch, & Moore, 
2006). The reported prevalence of anxiety among WHIV varies widely in the literature (from 1.91% 
to over 40%) (Goggin, Engelson, Rabkin, & Kotler, 1998; Morrison et al., 2002; Niu, Luo, Liu, 
Silenzio, & Xiao, 2016) depending on means of assessment of anxiety (Chander et al., 2006), types 
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of anxiety assessed, and differences in participants’ characteristics such as social-demographic 
factors and whether HIV is a recent diagnosis. 
Anxiety and alcohol use often co-occur among PHIV (Bing et al., 2001; Chandra, Ravi, Desai, 
& Subbakrishna, 1998; Lorra Garey et al., 2015) and both are independently associated with 
decreased medication adherence and viral suppression in PHIV (Chander et al., 2006). While anxiety 
is prevalent among PLWH, and often co-occurs with alcohol use, most studies examining the 
relationship between alcohol use and mental health symptoms among PHIV have focused on 
depression (L. Garey et al., 2015; Havlik, Brennan, & Karpiak, 2011; L'Akoa R, Noubiap, Fang, 
Ntone, & Kuaban, 2013; Sullivan, Goulet, Justice, & Fiellin, 2011; Sullivan et al., 2008; E. C. 
Williams et al., 2014). Research examining the relationship between anxiety and alcohol use among 
PHIV has been very limited (Chander et al., 2006; Lorra Garey et al., 2015). Even scarcer are studies 
that examine these relationships targeting WHIV. Furthermore, most existing studies in this area are 
cross-sectional (Bing et al., 2001; Chandra et al., 1998; Lorra Garey et al., 2015). However, because 
WHIV change their alcohol use patterns over time (Cook et al., 2013), existing studies may not have 
captured the full picture. Understanding the relationship between change in anxiety and change in 
alcohol use among WHIV may help promote gender-specific interventions that address both anxiety 
symptoms and alcohol use, ultimately reducing adverse outcomes associated with the two substances 
in this population. 
 
Retention in care 
Engagement in the medical care system for clinical appointments and treatment, is one step in 
the HIV Care Continuum (Kay et al., 2016) that is import for people living with human 
immunodeficiency virus (PHIV) to suppress viral load (Robbins et al., 2007; Sethi, Celentano, 
Gange, Moore, & Gallant, 2003) and decrease likelihood of death (Giordano et al., 2007; S. H. Lee et 
al., 2013; Mugavero et al., 2009). The extent of engagement was measured by retention in care 
(RIC) in three ways including medical visits at defined intervals such as the Institute of Medicine 
(IoM) index and the Department of Health and Human Services (DHHS) indicator (Rebeiro et 
al., 2014), missed clinical visits (Mugavero et al., 2014), or both (Horstmann, Brown, Islam, 
Buck, & Agins, 2010). In the US, unfortunately, a significant proportion of PHIV have poor 
engagement in HIV care (Mugavero, Amico, Horn, & Thompson, 2013; Robbins et al., 2007), even 
among those in Veteran Affairs Hospitals or Clinics where few financial barriers exist (Giordano et 
al., 2007). Rates of non-retention in care (RIC) among PHIV are high among existing studies, 
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ranging from 11% to 42% depending on socio-demographic, behavioral, and health profiles of the 
study population and approaches to measuring RIC (Giordano et al., 2007; Monroe et al., 2016b; 
Robbins et al., 2007; Yang, Yan, Liu, Huang, & Long, 2015). Poor RIC is the aftermath of mixed 
socio-cultural, economic, and health-system factors (Tiruneh, Galarraga, Genberg, & Wilson, 2016). 
According to previous studies, predictors of poor engagement in care include initiating ART at a 
young age (≤ 30 years), absence of non-HIV related comorbidities, high baseline CD4 cell count 
(>300 cells/μL) (Robbins et al., 2007), and low education level (Tiruneh et al., 2016; Yang et al., 
2015). In addition, in the qualitative part of a mixed-method study, researchers identified fear of 
stigma, care dissatisfaction, use of holy water (symbolizing spiritual blessing), and economic 
constraints to be factors that hindered RIC among PHIV (Tiruneh et al., 2016).  
 
Alcohol use, mental health symptoms, and retention in care among WHIV 
At-risk drinking for general population is defined as drinking >1 drinks (one drink contains 14 
grams of pure alcohol) per day for women (National Institute on Alcohol Abuse and Alcoholism, 
2016). For persons with comorbid conditions such as HIV, there may be increased risk for adverse 
outcomes even at lower levels of consumption (Bonacini, 2011). Although alcohol use was found to 
be associated with medication nonadherence (Beer & Skarbinski, 2014; Braithwaite et al., 2005; 
Carrico, Woolf-King, Neilands, Dilworth, & Johnson, 2014; Chitsaz et al., 2013; Conen et al., 2009; 
Herrmann et al., 2012; Holmes, Bilker, Wang, Chapman, & Gross, 2007; King et al., 2012; Lima et 
al., 2014; Ohl et al., 2013; Parsons, Rosof, & Mustanski, 2008; E. C. Williams et al., 2014; Woolf-
King, Neilands, Dilworth, Carrico, & Johnson, 2014) and delayed treatment (Koirala et al., 2017) 
among PHIV, there have been limited studies examining the effects of alcohol use on the likelihood 
of attending HIV clinical visits in this population (Koirala et al., 2017; Mugavero et al., 2013). There 
have been even fewer studies that examine this issue among women living with HIV (WHIV). This 
problem needs to be further studied because 1) drinking is more prevalent among WHIV than women 
not living with HIV (Neblett et al., 2011); 2) women are more vulnerable to the effects of alcohol 
than men due to decreased metabolism and lower proportion of water in their body (Cole-Harding & 
Wilson, 1987; Frezza et al., 1990); 3) women have an increased likelihood of delaying alcohol 
overuse treatment (Green et al., 2001).  
Another issue that needs to be specially attained to about WHIV is that metal health symptoms 
such as anxiety and depression are more prevalent among women compared with men in the general 
population and in the HIV-infected population (Chander & McCaul, 2003; McLean et al., 2011; 
Saadat et al., 2015; van den Heuvel et al., 2013). Those symptoms may negatively affect HIV-related 
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outcomes in this population (Chander et al., 2006). Although there are extensive literature 
demonstrating the negative relationship between mental health symptoms and medication adherence, 
there have not been much studies examining the relationship between mental health symptoms and 
likelihood of attending HIV clinical visits among PHIV, especially WHIV (Zuniga, Yoo-Jeong, Dai, 
Guo, & Waldrop-Valverde, 2016). 
Understanding the relationship between alcohol use, mental health symptoms such as 
depression and anxiety, and likelihood of attending HIV clinical visits among WHIV is important to 
improve retention in care, which is important given the disproportionately high and increasing HIV 
prevalence among women (Walter, Lundgren, Umez-Eronini, & Ritter, 2016). It may also help 
promote gender-specific alcohol and mental health symptoms reduction interventions that reduce 




The conceptual framework utilized in my dissertation was the modified Potential Mechanism 
of HIV Progression framework (Hahn & Samet, 2010). According to this modified framework, living 
with HIV and socio-demographic factors promote the development of mental health symptoms such 
as anxiety among PHIV. Anxiety then promotes PHIV to use alcohol. Then, there are two basic 
mechanisms of how alcohol use contributes to progression of HIV disease- biological mechanisms 
and behavioral mechanisms (Hahn & Samet, 2010). Biologic effects include weakened immune 
system (Szabo & Mandrekar, 2009), translocation of bacteria from the gut that induces the activation 
of HIV virus (Kumar et al., 2005), decreased nutrition absorption (Watzl & Watson, 1992), and 
decreased effectiveness of ATR (Lieber & DeCarli, 1970). Behavioral effects include decreased ART 
adherence, increased non-retention in care, and a high correlation between alcohol use and illicit 
substance use (Braithwaite et al., 2005). The two mechanisms lead to increased HIV progression and 




Source of data 
Data of the dissertation came from two concurrently recruited cohorts of WHIV. One was a 
randomized controlled trial (RCT) designed to test the effectiveness of a brief alcohol intervention 
(BI) among WHIV with baseline at-risk drinking (defined as 8 or more drinks/week, 2 or more binge 
drinking episodes [defined as 4 or more drinks/occasion] in the past six months, or TWEAK score 
≥2) (Chander, Hutton, Lau, Xu, & McCaul, 2015). The second cohort was a concurrently recruited 
sample of WHIV without at-risk drinking at baseline from the same clinic (Barai et al., 2016). The 
parent studies were registered at clinicaltrials.gov: NCT00127231 and were approved by the Johns 
Hopkins Medicine Institutional Review Board. 
Participants were recruited between March, 2006 and September, 2010 through several 
methods, including clinic flyers, provider referral, waiting room recruitment, and review of drinking 
data obtained from an audio-computer-assisted-self-interview (ACASI) routinely administered to 
patients who have consented to enroll in the HIV Clinical Cohort every six months (Chander et al., 
2015). Parent study inclusion criteria included women who 1) had a confirmed HIV infection; 2) 
received outpatient care at the Johns Hopkins HIV Clinic; 3) were 18 years of age or older; 4) were 
not receiving treatment for an alcohol use disorder (AUD); 5) not pregnant; and 6) had no history of 
psychosis at the time of enrollment. Women in the RCT had visits at baseline and three, six, and 
twelve months post-enrollment; women in the non-at-risk drinking cohort had visits at baseline, and 
six, and twelve months post-enrollment. For the purpose of this study, we used data at baseline, six 
months, and twelve months post-enrollment for both cohorts. 
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Chapter 2: Is Alcohol Use Associated with Increased Risk of Developing 
Adverse Health Outcomes Among Adults Living with Human 
Immunodeficiency Virus: A Systematic Review 
 
Abstract 
Background: Alcohol use is associated with many HIV-related behaviors that are associated with 
increased risk of reinfection, transmission, and poorer health outcomes in people living with HIV 
(PHIV). The population of middle aged and older PHIV is growing due to increased life longevity 
and aging trend.  
Methods: A systematic review across three databases was conducted to evaluate existing studies that 
examined the association between alcohol use and medication adherence, high-risk sex behaviors, 
HIV progression, depression, resource utilization, and survival among studies of PHIV with an 
average age of 40 and above. 
Results: Among the included 47 studies, most found a positive association between alcohol use and 
depression, risky sex behaviors, and resource utilization as well as a negative association between 
alcohol use and medication adherence among PHIV. The association between alcohol use and 
response to treatment was variable. The association between alcohol use and survival warrants 
further study due to lack of existing studies.  
Conclusions: The results of this review support that alcohol use negatively impacts middle aged and 
older PHIV in many aspects; however, there are lack of studies exclusively targeting older PHIV and 
more relevant studies in the future are needed. 
Key words: alcohol use; human immunodeficiency virus; health outcomes; HIV progression; 




At-risk drinking, defined here as drinking above the recommended limits (no more than 4 
drinks in one day for men [3 for women] and no more than 14 drinks in one week for men [7 for 
women]) is associated with adverse health outcomes in the general population ("Drinking levels 
defined," 2015). For persons with HIV [PHIV], they may face increased risk even at lower levels of 
consumption (Bonacini, 2011). For PHIV, alcohol use has been associated with not only increased 
risk for adverse physical outcomes such as liver damage (Barve et al., 2010) and more rapid virus 
growth (White & Hingson, 2013), but also with increased risk of depression (Rotheram-Borus, 
Tomlinson, Le Roux, & Stein, 2015), decreased medication adherence (Braithwaite et al., 2005), and 
increased engagement in high risk sexual behaviors (Neblett et al., 2011). 
          In one study with PHIV aged 50 and over, 57% of participants reported drinking alcohol in the 
past year, and 7% had severe unhealthy drinking (AUDIT-C>7) (Williams et al., 2014). Thus the use 
of alcohol in PHIV is a concern not only for younger adults but also for those in older cohorts. With 
the development of antiretroviral therapy (ART), PHIV now have a longer life expectancy if they 
receive proper treatment. The median survival for PHIV aged 50 years and above receiving treatment 
increased from 11.8 years during 1996-1999 to 22.8 years during 2006-2014 (Legarth et al., 2016). 
Almost one in five PHIV are aged 55 or older ("Drinking levels defined," 2015). This increased 
longevity has resulted in a similar trend that is occurring globally with a growing number of PHIV 
aged 40 and above ((UNAIDS), 2013).With advancing age, age-related changes occur, such as 
decreased memory and cognitive abilities that add to the challenges of properly managing HIV. 
Moreover, older PHIV are medically more complex than younger counterparts (Williams et al., 
2014), including being more likely to suffer from severe symptoms, concurrently having other 
chronic comorbidities, taking multiple medications, and having increased risks of liver toxicity 
(Centers for Disease Control and Prevention, 2014). The impact of drinking in this population is 
probably compounded by these existing conditions. Even the general population, as they age, become 
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more vulnerable to the negative effects of drinking. However, most existing studies targeted mainly 
the younger population rather than older population with HIV (Williams et al., 2014). 
          We found no systematic review of the literature examining the association between alcohol use 
and health outcomes targeting older PHIV. Although primary research on alcohol use and its 
associated outcomes exclusively targeting this age group are also lacking (Neblett et al., 2011), there 
is enough published research where the average age of the participants was 40 and above that 
allowed us to conduct a review on this issue. In an attempt to capture a population with a greater 
proportion of middle aged and older adults, we conducted a literature review that only included 
studies where the average age of the participants was 40 and above. The purpose of this systematic 
review was to evaluate existing studies on the association between alcohol use and medication 
adherence, engagement in high risk sex behaviors, resource utilization, HIV progression, depression, 
and survival in studies that included PHIV with an average age of 40 and above. Because alcohol use 
is a modifiable behavior, understanding the relationship between alcohol use and these variables can 
lead to the development of interventions tailored to levels of alcohol use to promote better health 
outcomes among the growing number of middle aged and older PHIV. 
REVIEW 
Data sources and search strategy 
A systematic review was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA), an evidence-based minimum set of items for reporting in 
systematic reviews and meta-analyses (Moher, Liberati, Tetzlaff, Altman, & Group, 2010). Three 
databases (MEDLINE, EMBASE, and CINHAL) were utilized with the help of a master’s prepared 
librarian. Because different databases possessed unique subject headings, each of the three databases 
was searched independently. The search terms used on MEDLINE were summarized on an online 














Studies were considered for inclusion if they met the following criteria: (1) descriptive studies 
containing primary data; (2) average age of the HIV-positive participants in the study was 40 or 
above; (4) the studies were published in English between 2005 and 2015; (5) examined the impact of 
alcohol use among PHIV in areas of medication adherence or ART treatment response or depression 
or/and sex behaviors or survival. Studies that were not published in English or published before 2005 
or not primary studies were excluded. The time period between 2005 and 2015 was chosen because 
literature older than this period would not have reflected more recent advances in ART. Studies in 
which researchers aimed to assess complications of HIV, such as tuberculosis and pneumonia, were 
also excluded.  
 
Search results 
The process for study selection was conducted in two stages: The first stage included an 
initial screening of titles and abstracts against the predetermined inclusion and exclusion criteria to 
identify relevant articles by two researchers. Following this, an evaluation of the full articles of those 
included studies was conducted. An initial search across the three databases identified 3,103 articles 
A 
 (hiv infections[mh] OR hiv[mh] OR hiv[tw] OR hiv-1[tw] OR hiv-2[tw] 
OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human 
immunodeficiency virus[tw] OR human immunodeficiency virus[tw] OR 
human immune-deficiency virus[tw] OR human immune-deficiency 
virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired 
immunodeficiency syndrome[tw] OR acquired immunodeficiency 
syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired 
immune-deficiency syndrome[tw] OR ((acquired immun*) AND 
(deficiency syndrome[tw]))) 
B 
(("Alcoholism"[Mesh]) OR "Alcohol Drinking"[Mesh] OR "Alcohol-
Related Disorders"[Mesh] OR alcohol drink* [tw] OR alcohol* [tw] OR 
alcohol consumpt* [TW] OR alcohol intake* [tw] OR alcohol abuse [tw])) 
C AND (middle aged [mh] OR aged [mh] OR "middle age" OR "middle aged" OR elderly [tiab] OR senior* [tiab]) 
Overall A AND B AND C 
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(1,555 articles on MEDLINE, 1048 on EMBASE, and 500 on CINAHL). After removal of duplicates 
(n=1033) and review of titles and abstracts, 239 were considered for potential inclusion. After full 
text reviews, 47 articles were excluded due to unmet criteria about the average age of the 
participants. Nine studies were excluded due to a publication date prior to 2005. Forty-three studies 
were excluded due to unmet criteria about study design. Ninety-three studies were excluded due to 
the fact that those studies did not look at the outcomes identified by the inclusion criteria. Finally, 47 
articles were included for this systematic review. Figure 1 presents a flowchart depicting the 





Information regarding author, publication date, study location, study design, purpose of the 
study, inclusion criteria, sample size, average or median age of the participants, outcomes measured, 
main findings, and limitations were manually extracted for each of the 47 studies (Table 2). To 
ensure the accuracy of the information, the content was double-checked by a second researcher. Any 
disagreement was resolved by a third researcher.  
Assessment of the methodological quality  
The methodological quality of the included studies was assessed based on the modified version 
of Research Evidence Appraisal Tool developed by Johns Hopkins Nursing Evidence-Based 
Practice: Model and Guidelines (Table 3) (Sandra Dearholt & Dang, 2012). Rigor of the sampling 
strategy, time of publication, purpose of the study, validity and reliability of the instrument, rigor of 
statistical analysis, and discussions of the conclusions and limitations of the study were assessed for 
each of the included papers and an overall quality rate was generated. High-quality papers were 
defined as offering consistent and generalizable results, sufficient sample size, adequate control, 
rigorous statistical analysis, and consistent recommendations based on research findings. Good-
quality papers were defined as offering reasonably consistent results, sufficient sample size for the 
study design, reasonable statistical analysis, and rationally consistent recommendations based on 
research findings. Low-quality papers were defined as offering little evidence with inconsistent 
results, insufficient sample size for the study design, and conclusions that cannot be drawn. 
 
Measures of key variables 
Alcohol use 
Since alcohol use is the main variable in this review and the way to measure alcohol use varied 
widely in the literature, it is important to understand how alcohol use was measured and defined 
among the included studies to compare their results. Among included studies, 16 studies used tools or 
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instruments focusing on screening for an AUD (Altice et al., 2011; Baum et al., 2010; Chitsaz et al., 
2013; L'Akoa R, Noubiap, Fang, Ntone, & Kuaban, 2013; Lima et al., 2014) or a diagnosis of AUD 
(Erickson, Becker, Shaw, Kasper, & Keynan, 2015; Gordon et al., 2006; Heinz, Fogler, Newcomb, 
Trafton, & Bonn-Miller, 2014; Henrich, Lauder, Desai, & Sofair, 2008; Justice et al., 2006; Kraemer 
et al., 2006; Obel et al., 2011; Ohl et al., 2013; Palepu et al., 2008; Samet et al., 2007; Sullivan, 
Goulet, Justice, & Fiellin, 2011). In the rest of the studies, alcohol use was defined related to at-risk 
use. Fifteen studies used AUDIT or AUDIT-C questionnaire that placed the participants into 
different categories such as non-hazardous drinking, hazardous drinking, problem drinking or used 
the score as a continuous variable to indicate the extent of risky drinking (Carrico, Woolf-King, 
Neilands, Dilworth, & Johnson, 2014; Garey et al., 2015; Gordon et al., 2006; Heinz et al., 2014; 
Jacob, Blonigen, Upah, & Justice, 2013; Justice et al., 2006; Justice et al., 2016; Kader, Seedat, 
Govender, Koch, & Parry, 2014; Kalichman et al., 2014; King et al., 2012; Malbergier, Amaral, & 
Cardoso, 2015; Parsons, Rosof, & Mustanski, 2008; Sullivan et al., 2011; Williams et al., 2014; 
Woolf-King, Neilands, Dilworth, Carrico, & Johnson, 2014); three studies used a validated calendar 
or Timeline Follow Back (TLFB) that categorized participants into heavy or non-heavy drinkers 
(Braithwaite et al., 2005; Samet et al., 2007; Sullivan et al., 2008); twelve studies used self-reported 
alcohol use (Arasteh & Des Jarlais, 2009; Barta et al., 2008; Barta, Tennen, & Kiene, 2010; Beer & 
Skarbinski, 2014; Chaudhry et al., 2011; Conen et al., 2009; Cunningham, Sohler, Berg, Shapiro, & 
Heller, 2006; Hasse et al., 2010; Havlik, Brennan, & Karpiak, 2011; Herrmann et al., 2012; Josephs 
et al., 2010; Kee et al., 2015; Sullivan et al., 2011); one study examined treatment services review 
(Stein et al., 2005); two studies used Audio-Computer Assisted Self-interviews (Hutton et al., 2013; 
Kowalski et al., 2012); one study used an additional severity index (Mugavero et al., 2006); one used 
a combination of different measures (Miguez-Burbano, Lewis, Fishman, Asthana, & Malow, 2009). 
Thus, among the included studies, different measures and definitions of alcohol use were adopted 
with no consistent methods across studies, which hampered our ability to incorporate and compare 
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study findings. How alcohol use was measured and defined in the included studies were summarized 
in Table 4.  
 
Medication adherence 
Sixteen studies evaluated medication adherence, including self-reported 30 day adherence to 
ART (Braithwaite et al., 2005; Williams et al., 2014), the number of days of antiretroviral drugs 
dispensed divided by the number of days on antiretroviral therapy (Lima et al., 2014; Ohl et al., 
2013), how often a dose of medication was missed in the previous four weeks (Conen et al., 2009), 
the adherence measure developed by the AIDS Clinical Trials Group (Beer & Skarbinski, 2014; 
Carrico et al., 2014; King et al., 2012; Woolf-King et al., 2014), achievement of >95% ART 
adherence (Chitsaz et al., 2013; Holmes, Bilker, Wang, Chapman, & Gross, 2007), the MED-OUT 
index (Ohl et al., 2013), cell-phone-based pill counts (Kalichman, Cain, & Simbayi, 2010; Mugavero 
et al., 2006), modified TLFB (Braithwaite et al., 2005), and at least 95% of all doses taken on a 
single day based on TLFB (Parsons et al., 2008). 
 
Risky sex behaviors 
Seven studies assessed risky sex behaviors, including condom use (Chaudhry et al., 2011; 
Stein et al., 2005), multiple partners (Stein et al., 2005), vaginal/anal sex, partners’ HIV status 
(Hutton et al., 2013), having sex with stable partners whose HIV status was reported to be negative 
or unknown or with occasional partners (Barta et al., 2008; Hasse et al., 2010), number of occasions 
in which they engaged in anal or vaginal sex for the period “last night” and the number of each of 
these occasions in which participants used a condom “from start to finish” (Barta et al., 2008; Barta 
et al., 2010), and the proportion of times condoms/female condoms were used during sexual activities 




Healthcare resource utilization 
Eight studies assessed resource utilization including outpatient visits, mental health visits, 
emergency department visits (Cunningham et al., 2006; Josephs et al., 2010), inpatient 
hospitalizations (Cunningham et al., 2007; Kraemer et al., 2006), whether the participant had a 
regular doctor (Cunningham et al., 2006), number of healthcare visits in the past six months (Gordon 
et al., 2006), medical disease profile (Justice et al., 2016), delayed treatment (Conen et al., 2009), and 
number of missed clinical appointments (Erickson et al., 2015).  
 
HIV progression 
Thirteen studies measured changes in viral load or CD4 cell count (Altice et al., 2011; Baum et 
al., 2010; Carrico et al., 2014; Heinz et al., 2014; Henrich et al., 2008; Kader et al., 2014; King et al., 
2012; Kowalski et al., 2012; Lima et al., 2014; Malbergier et al., 2015; Miguez-Burbano et al., 2009; 
Samet et al., 2007; Woolf-King et al., 2014). One study measured changes of thymus size (Miguez-
Burbano et al., 2009). One study measured severity of HIV-related symptoms, such as fatigue, 
physical symptoms, mood disturbance (Heinz et al., 2014). 
 
Depression 
Seven studies measured depression, using measurements of the Patient Health Questionnaire 
(L'Akoa R et al., 2013; Sullivan et al., 2011; Williams et al., 2014), Center for Epidemiologic Studies 
Depression Scale (Havlik et al., 2011; Sullivan et al., 2008), Beck Depression Inventory (Kee et al., 
2015), and The Inventory of Depression and Anxiety Symptoms (IDAS) (Garey et al., 2015). 
 
Survival 
Three studies evaluated survival, including survival from age 25 to 65 years (Obel et al., 2011), 




A total of 135,345 participants were included in the 47 studies. Thirty-eight studies included 
PHIV only and nine studies included both PHIV and non-infected adults. The sample size of each 
individual study ranged from 116 to 20,301, with the majority ranging between 400 and 1,000. Three 
studies were conducted in Canada (Erickson et al., 2015; Lima et al., 2014; Palepu et al., 2008), one 
in Switzerland (Conen et al., 2009), one in Cameroon (L'Akoa R et al., 2013), one in Korea (Kee et 
al., 2015), one in Australia (Herrmann et al., 2012), one in South Africa (Kader et al., 2014), and one 
in Denmark (Obel et al., 2011). The remaining 28 studies were conducted in the U.S. The date of 
publication ranged from 2005 to 2015. Fifteen studies were longitudinal studies and 32 were cross-
sectional. The mean age of participants in the studies ranged from forty (L'Akoa R et al., 2013; Stein 
et al., 2005) to above fifty (Williams et al., 2014).  
 
Alcohol use and medication adherence 
Thirteen studies (Beer & Skarbinski, 2014; Braithwaite et al., 2005; Carrico et al., 2014; 
Chitsaz et al., 2013; Conen et al., 2009; Herrmann et al., 2012; Holmes et al., 2007; King et al., 2012; 
Lima et al., 2014; Ohl et al., 2013; Parsons et al., 2008; Williams et al., 2014; Woolf-King et al., 
2014) assessed the association between alcohol use and medication adherence. All except two 
(Kalichman et al., 2014; Williams et al., 2014) found a negative relationship between the two 
variables. However, the study done by Williams et al. (Williams et al., 2014) yielded opposite 
findings and indicated that thirty-day ART adherence was not associated with alcohol use or alcohol 
use severity among 447 PHIV aged 50 and above with suboptimal adherence (non-adherence was 
defined as missing >1.5 days of medication or taking medications 2 hours early or late on >3 days in 
the 30 days prior to screening). It might be due to the fact that suboptimal adherence to ART was an 
inclusion criterion in that study; thus, its findings did not correspond with those in other studies 
including PHIV with a wide range of level of ART adherence. Another study did not find a 
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significant overall association between alcohol use and adherence to ART among PHIV; however, 
alcohol use was found to be significantly associated with nonadherence among participants who did 
not have sustained viral suppression (Kalichman et al., 2010). In addition, two studies found that 
even alcohol use of the partners of PHIV had an impact on medical adherence among HIV-infected 
men who have sex with men (MSM). HIV-infected MSM participants with partner-abstainers versus 
partner-drinkers had less self-efficacy to persevere in HIV treatment and reported lowered adherence 
(Carrico et al., 2014; Woolf-King et al., 2014). 
 
Alcohol use and depression 
A positive correlation between alcohol use and depression in PHIV with an average age 40 
and above was found in seven studies (Garey et al., 2015; Havlik et al., 2011; Kee et al., 2015; 
L'Akoa R et al., 2013; Sullivan et al., 2011; Sullivan et al., 2008; Williams et al., 2014); however, the 
associations varied based on participants’ drinking profiles. Williams et al. found that the prevalence 
of positive depression screening was the most common among PHIV aged 50 and above with severe 
unhealthy drinking (definitions based on AUDIT C score: drinking in past year [0], low-level 
drinking [1-3], mild-moderate unhealthy drinking [4-6], and severe unhealthy drinking [scores ≥7]) 
(Williams et al., 2014). However, Sullivan et al. found that after adjusting for other variables, only 
current alcohol dependence -defined by meeting diagnostic criteria in the past 6 months and assessed 
using the reference standard Composite International Diagnostic Interview- was independently 
associated with more depressive symptoms in PHIV with current or past alcohol problems (Sullivan 
et al., 2008). Sullivan, L et al. in a longitudinal study of U.S. Veterans suggested that depressive 
symptoms were significantly higher among hazardous and binge drinkers than in past and 
nonhazardous drinkers LWHIV, (Binge drinkers were defined as consuming 6 or more drinks on one 
occasion 3 or more times during the past year. Hazardous drinkers were defined by an AUDIT score 
of 5 (females) or 7 (males) or more (Sullivan et al., 2011). The differences in the results of the three 
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studies may be attributable to different inclusion criteria and how alcohol use was categorized in 
those studies. The first study only recruited PHIV aged 50 and above; the second study recruited 
PHIV with current or past alcohol problems; the third study recruited U.S. Veterans which mostly 
consisted of men with current or past alcohol problems. Although their results varied, all seven 
studies agreed that alcohol use and depression were positively correlated in some way.  
 
Alcohol use and risky sex behaviors 
Seven studies examined the relationship between alcohol use and risky sex behaviors; all found 
a positive association between the two variables (Arasteh & Des Jarlais, 2009; Barta et al., 2008; 
Barta et al., 2010; Chaudhry et al., 2011; Hasse et al., 2010; Hutton et al., 2013; Stein et al., 2005). 
Besides unprotected sex (Arasteh & Des Jarlais, 2009; Barta et al., 2008; Barta et al., 2010; 
Chaudhry et al., 2011; Hasse et al., 2010; Hutton et al., 2013; Stein et al., 2005). Risk behaviors 
found to be positively associated with alcohol use included engaging in anal sex, engaging in 
insertive anal sex among gay/bisexual men (Hutton et al., 2013), having unprotected sex with a 
causal partner (Arasteh & Des Jarlais, 2009), and having multiple partners (Hutton et al., 2013; Stein 
et al., 2005). 
 
Alcohol use and healthcare resource utilization 
Seven studies examined the association between alcohol use and healthcare resource 
utilization among PHIV (Conen et al., 2009; Cunningham et al., 2006; Cunningham et al., 2007; 
Erickson et al., 2015; Gordon et al., 2006; Josephs et al., 2010; Justice et al., 2016; Kraemer et al., 
2006); five found a positive association between the two variables (Cunningham et al., 2006; 
Cunningham et al., 2007; Josephs et al., 2010; Kraemer et al., 2006). Alcohol use was found to be 
positively associated with emergency department visits, hospitalizations (Cunningham et al., 2007; 
Josephs et al., 2010; Kraemer et al., 2006), incidence rates for outpatient and mental health visits 
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(Kraemer et al., 2006), likelihood of having a regular doctor (Cunningham et al., 2006), and 
concurrent presence of various medical diseases such as hypertension, diabetes, obstructive 
pulmonary disease, and bacterial pneumonia (Justice et al., 2016). Two studies found that alcohol use 
was associated with suboptimal healthcare utilizations including missed appointments (Erickson et 
al., 2015) and fewer outpatient visits (Gordon et al., 2006). Conen et al. found that alcohol use was 
not associated with delayed treatment (defined as percent of treatment-naïve individuals with CD4+ 
T-cell count <200 cells/ul across alcohol consumption categories) (Conen et al., 2009). 
 
Alcohol use and HIV progression 
Fourteen studies examined the association between alcohol use and HIV progression. Five 
studies (Altice et al., 2011; Conen et al., 2009; Kalichman et al., 2014; Kowalski et al., 2012; Samet 
et al., 2007) found that the association between alcohol use and HIV surrogate markers (CD4 cell or 
viral load) was not significant. Seven studies (Baum et al., 2010; Heinz et al., 2014; Henrich et al., 
2008; Kader et al., 2014; Lima et al., 2014; Malbergier et al., 2015; Woolf-King et al., 2014) found a 
negative association between alcohol use and response to treatment, including a smaller CD4 cell and 
viral load change from baseline after starting ART (Henrich et al., 2008; Lima et al., 2014), 
significant CD4 decline (Baum et al., 2010), lower CD4 count (Kader et al., 2014), greater HIV 
symptom severity such as fatigue, physical symptoms, and mood disturbance (Heinz et al., 2014), 
more likely to have CD4 cell count ≤200/mm3 (Malbergier et al., 2015), and higher odd of detectable 
viral load (Baum et al., 2010; Woolf-King et al., 2014). Moreover, in one study, the types of alcohol 
had an impact on HIV progression: liquor was associated with thymus deterioration and thus with 
poorer viro-immune outcomes after HAART than wine and beer. However, it is unclear why liquor is 
riskier than wine and beer (Miguez-Burbano et al., 2009). In addition, two studies found that even 
alcohol use of partners of PHIV had an impact on treatment response among men who have sex with 
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men (MSM) living with HIV. MSM participants with partner-abstainers versus partner-drinkers had a 
lower adherence and a higher viral load (Carrico et al., 2014; Woolf-King et al., 2014). 
 
Alcohol use and survival  
Three longitudinal studies examined the association between alcohol use and survival but 
yielded conflicting results. One study found that drug and alcohol dependence (diagnosis based on 
ICNARC code) was not independently associated with hospital mortality in PHIV admitted to the 
ICU (Palepu et al., 2008); however, the other two studies examining various levels of alcohol use 
yielded opposite findings. The Danish nationwide-population-based cohort study found that in PHIV 
with alcohol abuse (diagnosis based on ICD code) had decreased survival from age 25 to 65 years 
than those without alcohol abuse (Obel et al., 2011). In a Veterans Aging Cohort Study (VACS), 
risks of mortality and physiologic injury were higher among those with higher AUDIT-C (>3) 
compared to those with lower AUDIT-C (1-3) (Justice et al., 2016). The inconsistent results may be 
attributed to different inclusion criteria. The first study ascertained participants from ICU admissions; 
thus, their HIV symptoms or other comorbidities were probably more severe than participants in the 
second and third study.  
DISCUSSION 
Although the number and proportion of PHIV aged ≥40 years old has been increasing 
rapidly, the characteristics and impact of alcohol use are under-described in this age group (Williams 
et al., 2014). To our knowledge, this is the first systematic review on this topic. And it is done with 
rigor and strict adherence to the Prisma protocol. As such, this study makes a unique and meaningful 
contribution to the field. Many pioneered HIV studies were included including VACS (Braithwaite et 
al., 2005; Gordon et al., 2006; Jacob et al., 2013; Justice et al., 2006; Justice et al., 2016; Kraemer et 
al., 2006; Sullivan et al., 2011), Swiss Cohort study (Hasse et al., 2010; King et al., 2012), Western 
Australia HIV cohort (Herrmann et al., 2012), the Coping with HIV/AIDS in the Southeast (CHASE) 
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Study (Mugavero et al., 2006), and Korean HIV cohort study (Kee et al., 2015). We choose to 
conduct a systematic review rather than meta-analysis because measurements of our variables are so 
different across studies that it is close to impossible to extract a universal item for each outcome to 
do a meta-analysis. Moreover, the number of articles retrieved for each outcome is small. 
 Based on the 47 longitudinal and cross-sectional studies, most studies found a positive 
association between alcohol use and depression, risky sex behaviors, and healthcare resource 
utilization, as well as a negative association between alcohol use and medication adherence among 
PHIV aged 40 and above. The association between alcohol use and response to treatment was 
variable among the included studies. The association between alcohol use and survival warrant 
further study due to a lack of pertinent studies. These findings are important given the fact that HIV 
cohort is aging and number of aged PHIV is increasing. 
  This review gives directions for future studies in a number of ways. First, certain outcomes 
such as depression and medication adherence were assessed much more frequently than the outcomes 
of healthcare resource utilization and survival. Thus, some outcomes have not been examined 
thoroughly with a focus on the multiple co-existing factors. This may be related to the fact that some 
outcomes are easier and more feasible to be assessed than others. In addition, results regarding the 
association between alcohol use and response to treatment have been conflicting among the included 
studies. Thus, more studies are needed to examine this outcome. Moreover, it is important to study 
the impact of alcohol use on risky sex behaviors of PHIV with a more advanced age because, 
although the likelihood of having had any sex in the last 6 months decreased significantly as age 
increased (Stein et al., 2005), PHIV with an advanced age are still at risk for HIV transmission and 
reinfection via sex. The included studies on this topic were all cross-sectional studies; thus, it 
remained unknown whether sex activities changed due to changes of HIV status. Moreover, it is 
unclear whether alcohol use preceded sex activity or the other way around. Thus, more longitudinal 
studies are needed on this issue. Moreover, there is lack of studies targeting women LHIV aged 40 
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and above. Prior studies have demonstrated that women are more vulnerable to the toxic effects of 
alcohol use than men due to slower gastric metabolism of alcohol and less water contained pound for 
pound in the body (Cole-Harding & Wilson, 1987). However, many of the included studies targeted 
men (Carrico et al., 2014; Woolf-King et al., 2014) or mostly consist of men such as VACS 
(Braithwaite et al., 2005; Gordon et al., 2006; Jacob et al., 2013; Justice et al., 2006; Justice et al., 
2016; Kraemer et al., 2006; Sullivan et al., 2011). Future studies need to examine the impact of 
alcohol use targeting women age 40 and above LHIV. In addition, future studies are needed to follow 
PHIV long-termly and differentiate those with new onset of alcohol use from those with a long 
history of alcohol use. Studies have shown that people who started alcohol use after age 45 (late 
onset) differ from those who started drinking before age 25 (early onset) in many ways. The former 
group reported fewer detoxification episodes, had lower actual alcohol consumption, and had a 
higher rate of abstinence in the 12-month follow-up than the late onset group (Wetterling, Veltrup, 
John, & Driessen, 2003). Furthermore, among included studies, only one study (L'Akoa R et al., 
2013) identified newly infected PHIV from general PHIV. The rest of the included studies did not 
differentiate newly infected PHIV from all other PHIV. As people’s behaviors could change as a 
result of a change of their HIV status (Kalichman et al., 2010), future studies that differentiate newly 
infected PHIV from PHIV with a diagnosis for a long time are warranted. 
 This review has several limitations. First, most included studies consist of PHIV aged 40 or 
above as well as those aged below 40 due to lack of studies targeting PHIV aged 40 and above alone. 
Thus, the results of those studies were results of PHIV with a mixed range of ages. We tried to 
overcome this limitation by only including studies where the average age of the participants was 40 
and above to ensure that at least a substantial proportion of the participants in this review aged 40 
and above. Secondly, how alcohol use was defined and measured varied widely among the included 
studies, which hampered our ability to compare results. To increase comparability, we summarized 
how alcohol use was defined and measured among included studies with a clear summary and tables. 
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We believe that this table is very helpful for people to see how alcohol variable was defined and 
operationalized among studies of this area. Third, the participants are heterogeneous among the 
included studies, including hard-to-reach marginalized PHIV (Cunningham et al., 2007), imprisoned 
PHIV (Chitsaz et al., 2013), HIV-infected MSM (Woolf-King et al., 2014), HIV-infected veterans 
(Kraemer et al., 2006), and PHIV with illicit drug intake (Lima et al., 2014). Thus, the results of 
those studies may have limited generalizability to other populations and also limited comparability. 
Moreover, as we did not have the capacity in our author group to review non-English journals, we 
included only journal articles published in English in this review. Last but not the least, although we 
adopted very broad inclusion criteria, age is very often not prominently mentioned in the many 
studies targeting PHIV and thus they could be missed in this review. Despite of the limitations above, 
we believe that this review is meaningful given the fact that it illustrates how alcohol use was 
commonly defined and operationalized in literature, identifies a significant gap in research, and gives 
much direction for future studies.  
CONCLUSIONS 
           Findings are hypotheses-generating regarding the importance of developing alcohol-related 
educational interventions tailored to middle aged and older PHIV. It is important to take into account 
the full continuum of at-risk use of alcohol and the association with poorer outcomes in PHIV. 
Interventions to reduce alcohol use in the population should include individual level as well as 
modifiable environmental level risk factors that play a key role in determining the extent of alcohol 
use for the general population as well as PHIV. Given the findings of this review, clinicians should 
be more aware of the importance of addressing alcohol use across the continuum of use in PHIV 
aged 40 and above. Clinicians should incorporate alcohol Screening and Brief Intervention 
(ASBIRT), an evidence-based practice that includes the use of validated alcohol screening tools, the 
delivery of brief interventions (Chander, Hutton, Lau, Xu, & McCaul, 2015), and when indicated 
referral to alcohol treatment services. This has the potential to help reduce the potential negative 
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outcomes (such as risky sex behaviors, poor survival, and poor response to treatment) associated with 
at-risk alcohol use in PHIV aged 40 and above. The ultimate goal is to improve quality of life as well 
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To explore if the 
diagnoses of drug or 
alcohol dependence 
and HIV infections, as 





Drug and alcohol 
dependence were not 
independently 
associated with hospital 
mortality. 
single geographic area; 
no HIV confirmation 
test; patient's disease 
stage was not 
characterized by CD4 
or HAART exposure. 
Not all types of 


















To examine the 
association between 
alcohol problems and 
health care services 
use in HIV infected 
and HIV uninfected 
patients 
Alcohol problems are 
associated with greater 
outpatient, emergency 
department, and 
inpatient health care uti
lization in HIV-infected 
veterans. 
Unable to determine 
whether the participants 


















AUDIT-C To assess alcohol use among older PLWH 




substance use history. 
Did not assess alcohol 
use over time. Sample 


















To assess the 
relationship between 
alcohol and illicit 
substance use on 
HAART outcomes 
Individuals with a 
history of both alcohol 
and injection drug use 
had a higher likelihood 
of experiencing the 
worst immunologic and 
virologic 
responses, mostly due 
to poor adherence. 
Certain marginalized 
populations were over 
sampled. Alcohol 
consumption was not 
measured directly. 



















To examine if alcohol 
was associated with 
risk taking behavior 
in HIV infected 
persons 
All measures of alcohol 
use were significantly 
associated with any 
sexual activity and with 




report of results can 












To evaluate the 
impact of varying 




time in patients with 




and binge drinkers have 
depressive symptoms 
that are more severe 
than non-hazardous and 
non-drinkers and 
similar to those with 
alcohol abuse or 
dependence. 
The cohort consist of 
U.S. Veterans who 
were mostly men. self-



















To examine the 
impact of alcohol use 
on depressive 




Alcohol use was 
associated with more 
depressive symptoms in 
HIV-infected patients 
with alcohol problems. 
Heavy depressive 
symptoms at baseline 
may have masked some 
of the impact of alcohol 

























To evaluate the 
impact of hazardous 
versus non-hazardous 
alcohol use on the 
health status of HIV-
infected individuals 
receiving HAART. 
Liquor was associated 
with thymus 
deterioration and thus 
with poorer viro-




seemed to be small. 














To study self-report 
alcohol consumption 
and its association 




was associated with 
non-adherence to ART 
Could not infer causal 
relationships. Self-
reported information 
can be biased. 












To examine the 
impact of problematic 
alcohol use on 
cognitive functions 
among PHIV 
Problematic alcohol use 
was associated with 
lower total memory 
functioning 
Self-report 
measurement of HIV 


























use with HIV disease 
management among 
men who have sex 
with men 
Abstainers compared to 
hazardous drinkers, had 
higher self-efficacy to 
follow HIV treatment 
Cross-sectional studies 
cannot generate causal 
relationships. Age, 
race, and relationship 
length limit 
generalizability of the 
study. 
Samet et al., 
(2007), US 
longitudina







To assess the relation 
between alcohol 
consumption and 





impacted the CD4 cell 
count of HIV infected 
persons not receiving 
ART. 
Participants were not 
recruited at the time of 
seroconversion and 
followed for their 
alcohol use, CD4 cell 

























among HIV infected 
population in jail 
Alcohol use severity 





Self-report data could 
be biased. The 30-day 
pre-incarceration 
period may introduce 
bias. 
















patients were more 
likely than those who 
were not depressed to 
have experienced 
alcohol abuse. 
Patients from isolated 
rural areas were not 
included. The 























To examine the 
impact of non-HIV 
and HIV Risk Factors 
on Survival in PHIV 
on HAART 
Survival was lower in 
PHIV with alcohol 
abuse. 
Only PWHIV aged 25–
64 were included. 
Smoking status was not 















To examine factors 
associated with health 




visits were associated 
with heavy alcohol use. 
There are no clear 
means to identify and 
recruit hard-to-reach 
populations who were 
not in care, or were 
intermittently in care. 










To evaluate hazardous 





was associated with 
depressive and anxiety 
symptoms, and HIV 
symptoms distress. 
Cross-sectional study 
did not identify 
mediating factors. Self-
report measures were 
subjective. 












whether depression in 
elders LHIV are 
associated with 




with increased alcohol 
use. 
Modest correlations 
could not infer 
causality or direction of 
associations. 










To determine the 





Current drinking was 
associated with 
increased anxiety and 
depressive symptoms. 
Some factors relevant 










40 sexual risk behaviors 
self-report 
questionnaire 
To assess at-risk 
drinking and injection 
and sexual risk 
behaviors of HIV-
positive injection drug 
users entering drug 
treatment in New 
York City 
At-risk drinkers were 
more likely to engage 
in unprotected sex with 
a casual partner. 
No measure of 
frequency of binge 
drinking; dichotomous 
measure of alcohol use 
was rough. 



















prior to sex 
significantly affected 
rate of unprotected sex. 
Cross-sectional design 
could not infer 
causality. 



















living with HIV/AIDS 
Findings support the 
moderating effects of 
high negative affect 
and sexual craving on 
the association between 
alcohol use and 
unprotected sex 
Diary adherence was 
low. Self-report data 











To explore HIV 
transmission risk 
behaviors in PHIV 
Alcohol use in previous 
30 days was 
significantly associated 
with risky sex. 
no uniform system of 
treatment 
assignment across sites; 
no randomization of 
participants 












To study the 
frequency, changes 




Moderate or severe 
alcohol use was 
associated with 
unprotected sex. 
uncertainty on accuracy 
of self-reported 
information about 
sexual behavior, illicit 

















To examine the 
association between 
alcohol use and risky 
sexual behaviors in 
PHIV 
Infrequent drinkers did 












41 access to healthcare 
face to face 
interview 
To investigate the 
associations between 
specific types of 
substances of abuse 
and access to HIV 
health care 
PHIV with binge 
alcohol use were 
more likely to have a 
regular doctor than 
those without binge 
alcohol use. 
modest sample size; 
health care access data 







above 40 care outcomes chart review 
To understand the 
impact of substance 
use on care outcomes 
for PHIV in Manitoba 
Abused alcohol was 
associated with missed 
appointments. 
Retrospective study led 
to potential 
underreporting of 










48.7 healthcare utilization AUDIT 
To evaluate the 
impact of 
homelessness and 
alcohol use on 
utilization of health 
services among PHIV 
Hazardous drinking and 
current homelessness 
were associated with 
<2 outpatient clinic 
visits. 
Multivariable analyses 
on health care 
utilization were related 
to hazardous alcohol 
consumption but not 



















utilization and clinical 
and 
sociodemographic 
correlates of ED use 
among PHIV 





of ED utilization; a 
large proportion of 
patients had missing 
CD4 count and HIV-1 
RNA data.  
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To explore whether 
level of exposure to 
alcohol is associated 
with medical disease 
and whether the 
association depends 
upon the proximity of 
alcohol use 
Alcohol use was 
significantly associated 
with various medical 
diseases. 
Few women were 
included. less complete 
data on drug and 
cigarette use 
Justice et al., 
(2016), US 
longitudina







To examine the 
association between 
alcohol exposure and 
mortality in PHIV 
through July, 2014 
PHIV experienced 
increased mortality and 
physiologic injury at 
higher levels of alcohol 
use compared with 
lower use. 
Accurate measurement 
of exposure to alcohol 
was challenging. Non-













To ascertain the 
prevalence of 
substance use among 





drinkers and correlated 
with both early 
















temporal and dose 
response relationships 
between alcohol use 
and medication 










use may underestimate 

















relationship factor as 
correlates of stimulant 
use and HIV disease 
management among 
men who have sex 
with men 
Partner-level alcohol 
use was independently 
associated with greater 
odd of reporting perfect 
3-day ART adherence. 
Stimulant use was 
assessed using self-
report measures that 
did not adequately 
characterize 
patterns of use, route of 
administration, or 
screening for the 
presence of stimulant 
use disorder. 
Ohl et al., 
(2013), US 
longitudina








LHIV in the US. 
Rural veterans were 
less likely to have an 
alcohol use disorder; 
rural veterans had more 
advanced immune 
compromise at care 
entry as evidenced by 
lower CD4 counts 
(median CD4 ranging 
from 300 among urban 
veterans to 247 among 
rural-small 
town/remote veterans 
VA healthcare differs 
from non-VA care, 
which may limit 
generalizability of 
study findings. 
Veterans with HIV are 
almost all male. 





45.9 ART adherence AUDIT 
To investigate the 
association of 






PHIV who smoke 
Nicotine dependence, 
illicit drug use, and 
alcohol use are 
potentially formidable 
barriers to ART 
adherence among 
PLWHA who smoke. 
analysis of cross-
sectional data and 
reliance on self-report 
















To examine alcohol 
use associated with 
sustained viral 
suppression as well as 
medication adherence 
among PHIV who 
drink alcohol and take 
ART. 
Alcohol use was 
associated with 
nonadherence among 
participants who did 
not have sustained viral 
suppression 
A convenience sample 
cannot be considered 
representative of PHIV. 
Sample came from 
clinical services that 
varied in adherence 
assistance and 
substance use 
treatment. Study relied 
on self-report 
instruments. 











To assess if self-
reported adherence is 





adherence in PHIV 
Factors associated with 
lower adherence 
included younger age, 
female gender, 
depression, stimulant 
use, binge alcohol use, 
greater than once-daily 
dosing, longer time 
since HIV diagnosis, 
and patient beliefs. 
Self-reported adherence 













To determine whether 




and poor adherence 
among PHIV 




temporal and dose 
response 
relationship to poor 
adherence. 
Adherence was 
measured with an 
adapted instrument that 




primarily male and 
















To evaluate the 
longitudinal 
association of alcohol 




(ART) among PHIV 
There was no 
statistically significant 
difference in CD4 T-
cell count by average 
drinks per drinking day 
at any frequency of 
alcohol use irrespective 
of sex or viral 
suppression 
Sample may not have 
included the heaviest 
drinkers. Limited to 
populations similar to 
our study sample, 




Alcohol use was 
measured by self-report 











To determine the 
generalizability of 
these findings to a 
sample of midlife 





veterans in treatment 
for HIV and veterans 
in treatment for non-
HIV medical issues. 
Both the HIV+ and 
non-HIV groups 
exhibited 4 patterns of 
drinking. SC drinkers 
had younger ages of 
onset for drinking and 
longer duration of 
smoking. SC drinkers 
also had the highest 
rates of cocaine use. 
Within the HIV+ 
subsample, SC and LO 
drinkers increased their 
drinking after their HIV 
diagnosis. 
Analyses did not 
contain precise 
information regarding 
date of HIV diagnosis. 
The investigator did not 













To assess the 
association between 
alcohol and drug use 
and CD4 cell count 
among PHIV on ART 
in an urban HIV 
reference center. 
Alcohol dependence 
seems to be associated 
with low CD4 cell 
count in HIV-positive 
patients 
self-report 
questionnaire to assess 
adherence to ART in 
the past week; 
the cross-sectional 
design of this study 
may impair our 












35.83 drug use AUDIT; self-report 
To establish the 
prevalence of 
hazardous use of 
alcohol and drug 
problems among 
patients attending a 
representative sample 
of HIV clinics in 
Cape Town and to 
investigate the role of 
such substance use in 
health status and 
disease progression 
Hazardous and harmful 
use of alcohol was a 
statistically significant 
and important 
determinants of lower 
CD4 counts, TB 
positive status and the 
likelihood of patients 
being on ARVs. 
Sample may not be 
representative of the 
HIV treatment seeking 
population across South 
Africa. 
Alcohol and drug use 
was measured by self-
reports and were not 
confirmed by 
laboratory testing. 






















To determine factors 
that may contribute to 
HIV progression 
Being on ART was 
negatively associated 

















To examine the 
association of alcohol 
abuse and injection 
drug use (IDU) with 
the immunologic and 




in urban community 
health clinics 
many patients at urban 
health clinics have a 
history of either 
injection drug use or 
alcohol abuse, and that 
injection drug use is 
negatively associated 
with the immunologic 
response to HAART in 
urban HIV-infected 
individuals 
It was not possible to 
differentiate between 
active and past alcohol 
abuse or IDU in our 
study; patients were on 
different combination 
antiretroviral therapies, 
some with protease 
inhibitors and some 
without. 
Baum et al., 
(2011), US 
longitudina







To examine the 
associations of 
alcohol use with HIV 
disease progression, 
measured by CD4 cell 
count decline and 
HIV viral load, in a 
cohort of PHIV with 
drug use 
Frequent alcohol 
intake, as well as the 
combination of 




This study was a 
secondary subset 
analysis of a 
longitudinal nutrition 
study of a cohort of 
HIV-seropositive 














To examine whether 
lifetime traumatic 
events including 
physical and sexual 
abuse, are associated 
with antiretroviral 
nonadherence 
Increased severity was 


























Definitions and Measurements of Alcohol Use 
Type of 





score of addiction severity 
alcohol  
Altice et al., 
(2011) 
Alcohol and drug abuse 
questionnaire and 
medical record 
patterns, changes and frequency 
of use and confirmation by 
medical record 
Baum et al., 
(2011) 
Alcohol Severity Index 
(ASI) 
alcohol related DSM-IV  Chitsaz et 
al., (2013) 
1. Did the researcher identify what is known and not known about 
the problem and how the study will address any gaps in 
knowledge?  
Yes No  
2. Was the purpose of the study clearly presented?  Yes No  
3. Was the study conducted within 10 years  Yes No  
4. Were data collection methods described clearly?  Yes No  
5. Were the instruments reliable (Cronbach’s alpha >=0.7)?  Yes No NA 
6. Was the validity of the instrument discussed?  Yes No NA 
7. If tables were presented, was the narrative consistent with the 
content?  Yes No NA 
8. Were study limitations identified and addressed?  Yes No  
9. Were conclusions based on results?  Yes No  
Quality Rating based on Quality Appraisal  
A High quality: consistent, generalizable results; sufficient sample size for the study 
design; adequate control; definitive conclusions; consistent recommendations based 
on research findings  
B Good quality: reasonably consistent results; sufficient sample size for the study 
design; some control, and fairly definitive conclusions; reasonably consistent 
recommendations based on research findings  
C Low quality or major flaws: little evidence with inconsistent results; insufficient 
sample size for the study design; conclusions cannot be drawn 
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Patient chart review 




alcohol abuse or dependence Gordon, A et 
al. (2006) 
Medical record 
diagnosis of alcohol abuse Henrich et 
al., (2007) 
The Structured Clinical 
Interview-Non-Patient 
Version for DSM-IV 
alcohol abuse or dependence Heinz et al., 
(2014) 
ICD-9 codes 
abuse or dependence Justice et al., 
(2006) 
Alcohol-related ICD-9-
CM codes  
alcohol-related diagnoses or 
complications between October 




no indication of a history of  
alcoholism(0-1), having an 
indication of a history of 
alcoholism (2-3), or having a 
confirmed history of alcoholism 
(4) 
Lima et al., 
(2014) 
CAGE 
alcohol abuse (≥2) L'akoa et al., 
(2013) 
ICD codes 
alcohol/drug abuse reported as 
the route of HIV transmission or 
hospital contacts before the index 
date 
Obel et al., 
(2011) 
ICD-9 codes diagnosis of alcohol use disorder Ohl et al., (2013) 
The Intensive Care 
National Audit and 
Research Council 
(ICNARC) codes 
alcohol or drug dependence at 2 
hospitals between January 1999 
and January 200? 





meeting diagnostic criteria of 
alcohol dependence in the past 6 
months 
Samet et al., 
(2007) 
ICD-9 codes  
alcohol abuse or dependence 
diagnosed in the year prior to or 




 AUDIT  problematic alcohol use (continuous variable) 




AUDIT alcohol related problems (≥8) Jacob et al., (2012) 
AUDIT harmful alcohol use (≥8) Malbergier et al., (2014) 
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AUDIT abstainers (0), nonhazardous (1-7) or hazardous (≥ 8) 
King et al., 
(2014) 




abstainers (0), nonhazardous 
drinkers (1-7), hazardous drinkers 
(≥ 8) 
King et al., 
(2014) 
AUDIT 
abstinence or low-risk drinking 
(0-7), hazardous drinking (8-15), 
harmful drinking (16-19), and 
dependence (20-40) 
Kader et al., 
(2013) 
AUDIT-C  
non-drinking (0), low-level 
drinking (1-3), mild-moderate 
Unhealthy drinking (4-6), or 




hazardous drinking (>8) 
and non-hazardous drinking (0-8) 
Garey et al., 
(2014) 
AUDIT 
hazardous drinking (AUDIT 






“hazardous” drinker ( 
≥6 drinks at a time; >14 
drinks/week for men or >7 
drinks/week for women or an 
overall AUDIT score > 8) 
moderate drinker (alcohol use at 
any time), lifetime abstainer (no 
record of any alcohol 
consumption) 
Justice et al., 
(2006) 
AUDIT-C 
integers of AUDIT-C scores Justice et al., 
(2015) 
AUDIT 
problem level drinking (>8) Kalichman et 
al., (2014) 
AUDIT 
problem level drinking (>8) Parsons et 
al., (2008) 
AUDIT 
cumulative AUDIT score King et al., 
(2012) 
AUDIT 
cumulative AUDIT score Carrico et 
al., (2014) 
Calendar method 
heavy drinking (> 14 drinks per 
week or ≥5 drinks on a single 
occasion for men <66 years 
old; >7 drinks per week or ≥4 
drinks on a single occasion for 
men ≥66 years old and all 




women), moderate alcohol use 
(any drinking less than heavy) 
Calendar method 
heavy drinking (> 4 drinks on 1 
day or > 14 drinks per week on 
average for men; > three or > 





abstainers (no alcohol 
consumption in the previous 30 
days); non-binge drinkers (no 
day on which ≥5 drinks were 
consumed); binge drinkers (≥5 
drinks within a calendar day at 




Combination of the 
Physician’s guide of the 
National Institute on 
Alcohol Abuse and 
Alcoholism, American 
Association, CAGE, 
AUDIT and ADS 
preferring to drink only liquor 
group, and preferring to drink 
only beer or wine group 
Burbano et 
al., (2009) 
Self-reported alcohol use 
light (<20g for women and <40g 
for men), moderate (20-40g for 
women and 40-60g for men), or 
severe health risk (>40g for 
women and >60g for men) 
Conen et al., 
(2009) 
Self-reported alcohol use 
binge drinking (5≥drinks in one 
sitting for men and 4≥drinks in 
one sitting for women) 
Beer et al., 
(2014) 
Self-reported alcohol use 
binge drinkers (6 or more drinks 
on one occasion 3 or more times 






no alcohol use group (no alcohol 
intake), low use group (alcohol 
intake < once a month or 
1–3 times a month, and never 
consumed > 5 drinks in a single 
day), the frequent/binge group 
(> 5 drinks on any 
occasion in the last 3 and/or 
alcohol at least once a week) 
Hutton et al., 
(2013) 
ACAIS 
average number of alcoholic 





day and number of days of 
alcohol consumption in a week 
Addition Severity Index 
(ASI) 
ASI scores measuring alcohol use 





severe (female, 140 g/day; male, 
160 g/day), moderate (female, 
20–40 g/day; male, 40–60 g/day), 
and light use (female, 20 g/day; 
male, 40 g/day) 
Hasse et al., 
(2010) 
Person to person 
interview 
hazardous (>14 drinks per week 




Self-reported alcohol use 
alcohol lifetime (yes or no) 
alcohol in last 3 months (yes or 
no) 
Havlik et al., 
(2011) 
Self-report alcohol use 
current drinker (yes or no), ex-
drinker (yes or no), non-drinker 
(yes or no) 
Kee et al., 
(2015) 
Self-report alcohol use 
at risk drinkers (men > 14 drinks 
and women > 7 drinks in a week 
during the prior 6 months) 
Arastah et 
al., (2009) 
Self-report alcohol use 
number of standard drinks Barta et al., 
(2008) 
Self-report alcohol use 
number of standard drinks using 
daily diary 
Barta et al., 
(2010) 
Self-report alcohol use 
lifetime history of alcohol use Chaudhry et 
al., (2011) 
Self-report alcohol use 





“binge alcohol users” (≥5 drinks 
on a typical day at least two times 
per month when they drank 
alcohol during the past year) 
Cunningham 
et al., (2006) 
Treatment Services 
Review 
hazardous drinking (≥1 binge 
drinking episodes or if the 
participant exceeded an average 
of 14 drinks [7 drinks for women] 
per week) 














Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., . . . 
Collaborative, B. (2011). HIV treatment outcomes among HIV-infected, opioid-dependent 
patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: 
Results from a multisite study. Journal of Acquired Immune Deficiency Syndromes, 56 Suppl 
1, S22-S32. doi:10.1097/QAI.0b013e318209751e 
Arasteh, K., & Des Jarlais, D. C. (2009). At-risk drinking and injection and sexual risk behaviors of 
HIV-positive injection drug users entering drug treatment in New York City. AIDS Patient 
Care and STDs, 23, 657-661. doi:10.1089/apc.2009.0027 
Barta, W. D., Portnoy, D. B., Kiene, S. M., Tennen, H., Abu-Hasaballah, K. S., & Ferrer, R. (2008). 
A daily process investigation of alcohol-involved sexual risk behavior among economically 
disadvantaged problem drinkers living with HIV/AIDS. AIDS and Behavior, 12, 729-740. 
doi:10.1007/s10461-007-9342-4 
Barta, W. D., Tennen, H., & Kiene, S. M. (2010). Alcohol-involved sexual risk behavior among 
heavy drinkers living with HIV/AIDS: Negative affect, self-efficacy, and sexual craving. 
Psychology of Addictive Behaviors, 24, 563-570. doi:10.1037/a0021414 
Barve, S., Kapoor, R., Moghe, A., Ramirez, J. A., Eaton, J. W., Gobejishvili, L., . . . McClain, C. J. 
(2010). Focus on the liver: Alcohol use, highly active antiretroviral therapy, and liver disease 
in HIV-infected patients. Alcohol Research & Health, 33, 229-236.  
43 
 
Baum, M. K., Rafie, C., Lai, S., Sales, S., Page, J. B., & Campa, A. (2010). Alcohol use accelerates 
HIV disease progression. AIDS Research and Human Retroviruses, 26, 511-518. 
doi:10.1089/aid.2009.0211 
Beer, L., & Skarbinski, J. (2014). Adherence to antiretroviral therapy among HIV-infected adults in 
the United States. AIDS Education and Prevention, 26, 521-537. 
doi:10.1521/aeap.2014.26.6.521 
Bonacini, M. (2011). Alcohol use among patients with HIV infection. Annals of Hepatology, 10(4), 
502-507.  
Braithwaite, R. S., McGinnis, K. A., Conigliaro, J., Maisto, S. A., Crystal, S., Day, N., . . . Justice, A. 
C. (2005). A temporal and dose-response association between alcohol consumption and 
medication adherence among veterans in care. Alcoholism, Clinical and Experimental 
Research, 29, 1190-1197.  
Carrico, A. W., Woolf-King, S. E., Neilands, T. B., Dilworth, S. E., & Johnson, M. O. (2014). 
Stimulant use and HIV disease management among men in same-sex relationships. Drug and 
Alcohol Dependence, 139, 174-177. doi:10.1016/j.drugalcdep.2014.03.025 
Centers for Disease Control and Prevention. (2014). HIV among people aged 50 and over. Retrieved 
from http://www.cdc.gov/hiv/group/age/olderamericans/index.html 
Chander, G., Hutton, H. E., Lau, B., Xu, X., & McCaul, M. E. (2015). Brief intervention decreases 
drinking frequency in HIV-infected, heavy drinking women: Results of a randomized 
controlled trial. Journal of Acquired Immune Deficiency Syndromes, 70, 137-145. 
doi:10.1097/QAI.0000000000000679 
Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J., Estrada, B., . . . Collaborative, B. 
(2011). Participant characteristics and HIV risk behaviors among individuals entering 
integrated buprenorphine/naloxone and HIV care. Journal of Acquired Immune Deficiency 
Syndromes, 56 Suppl 1, S14-21. doi:10.1097/QAI.0b013e318209d3b9 
44 
 
Chitsaz, E., Meyer, J. P., Krishnan, A., Springer, S. A., Marcus, R., Zaller, N., . . . Altice, F. L. 
(2013). Contribution of substance use disorders on HIV treatment outcomes and antiretroviral 
medication adherence among HIV-infected persons entering jail. AIDS and Behavior, 17 
Suppl 2, S118-127. doi:10.1007/s10461-013-0506-0 
Cole-Harding, S., & Wilson, J. R. (1987). Ethanol metabolism in men and women. Journal of Studies 
on Alcohol, 48 (4), 380-387.  
Conen, A., Fehr, J., Glass, T. R., Furrer, H., Weber, R., Vernazza, P., . . . Swiss, H. I. V. C. S. (2009). 
Self-reported alcohol consumption and its association with adherence and outcome of 
antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14 (3), 349-357.  
Cunningham, C. O., Sohler, N. L., Berg, K. M., Shapiro, S., & Heller, D. (2006). Type of substance 
use and access to HIV-related health care. AIDS Patient Care and STDs, 20, 399-407. 
doi:10.1089/apc.2006.20.399 
Cunningham, C. O., Sohler, N. L., Wong, M. D., Relf, M., Cunningham, W. E., Drainoni, M. L., . . . 
Cabral, H. D. (2007). Utilization of health care services in hard-to-reach marginalized HIV-
infected individuals. AIDS Patient Care and STDs, 21, 177-186. doi:10.1089/apc.2006.103 
Drinking levels defined. (2015).   Retrieved from https://www.niaaa.nih.gov/alcohol-
health/overview-alcohol-consumption/moderate-binge-drinking 
Erickson, A., Becker, M., Shaw, S., Kasper, K., & Keynan, Y. (2015). Substance use and its impact 
on care outcomes among HIV-infected individuals in Manitoba. AIDS Care, 27, 1168-1173. 
doi:10.1080/09540121.2015.1035634 
Garey, L., Bakhshaie, J., Sharp, C., Neighbors, C., Zvolensky, M. J., & Gonzalez, A. (2015). 
Anxiety, depression, and HIV symptoms among persons living with HIV/AIDS: The role of 
hazardous drinking. AIDS Care, 27, 80-85. doi:10.1080/09540121.2014.956042 
Gordon, A. J., McGinnis, K. A., Conigliaro, J., Rodriguez-Barradas, M. C., Rabeneck, L., Justice, A. 
C., & Team, V.-P. (2006). Associations between alcohol use and homelessness with 
45 
 
healthcare utilization among human immunodeficiency virus-infected veterans. Medical 
Care, 44, S37-43. doi:10.1097/01.mlr.0000223705.00175.3d 
Hasse, B., Ledergerber, B., Hirschel, B., Vernazza, P., Glass, T. R., Jeannin, A., . . . Swiss, H. I. V. 
C. S. (2010). Frequency and determinants of unprotected sex among HIV-infected persons: 
The Swiss HIV cohort study. Clinical Infectious Diseases, 51, 1314-1322. 
doi:10.1086/656809 
Havlik, R. J., Brennan, M., & Karpiak, S. E. (2011). Comorbidities and depression in older adults 
with HIV. Sex Health, 8, 551-559. doi:10.1071/SH11017 
Heinz, A. J., Fogler, K. A., Newcomb, M. E., Trafton, J. A., & Bonn-Miller, M. O. (2014). 
Problematic alcohol use among individuals with HIV: Relations with everyday memory 
functioning and HIV symptom severity. AIDS and Behavior, 18, 1302-1314. 
doi:10.1007/s10461-013-0602-1 
Henrich, T. J., Lauder, N., Desai, M. M., & Sofair, A. N. (2008). Association of alcohol abuse and 
injection drug use with immunologic and virologic responses to HAART in HIV-positive 
patients from urban community health clinics. Journal of Community Health, 33, 69-77. 
doi:10.1007/s10900-007-9069-1 
Herrmann, S. E., McKinnon, E. J., Williams, L. J., John, M., Mallal, S., Lucas, M., & Nolan, D. A. 
(2012). Use of alcohol, nicotine and other drugs in the Western Australian HIV cohort study. 
Sex Health, 9, 199-201. doi:10.1071/SH11085 
Holmes, W. C., Bilker, W. B., Wang, H., Chapman, J., & Gross, R. (2007). HIV/AIDS-specific 
quality of life and adherence to antiretroviral therapy over time. Journal of Acquired Immune 
Deficiency Syndromes, 46, 323-327. doi:10.1097/QAI.0b013e31815724fe 
Hutton, H. E., McCaul, M. E., Chander, G., Jenckes, M. W., Nollen, C., Sharp, V. L., & Erbelding, 
E. J. (2013). Alcohol use, anal sex, and other risky sexual behaviors among HIV-infected 
women and men. AIDS and Behavior, 17, 1694-1704. doi:10.1007/s10461-012-0191-4 
46 
 
Jacob, T., Blonigen, D. M., Upah, R., & Justice, A. (2013). Lifetime drinking trajectories among 
veterans in treatment for HIV. Alcoholism, Clinical and Experimental Research, 37, 1179-
1187. doi:10.1111/acer.12071 
Josephs, J. S., Fleishman, J. A., Korthuis, P. T., Moore, R. D., Gebo, K. A., & Network, H. I. V. R. 
(2010). Emergency department utilization among HIV-infected patients in a multisite 
multistate study. HIV Medicine, 11, 74-84. doi:10.1111/j.1468-1293.2009.00748.x 
Justice, A. C., Lasky, E., McGinnis, K. A., Skanderson, M., Conigliaro, J., Fultz, S. L., . . . Team, V. 
P. (2006). Medical disease and alcohol use among veterans with human immunodeficiency 
infection: A comparison of disease measurement strategies. Medical Care, 44, S52-60. 
doi:10.1097/01.mlr.0000228003.08925.8c 
Justice, A. C., McGinnis, K. A., Tate, J. P., Braithwaite, R. S., Bryant, K. J., Cook, R. L., . . . Fiellin, 
D. A. (2016). Risk of mortality and physiologic injury evident with lower alcohol exposure 
among HIV infected compared with uninfected men. Drug Alcohol Depend, 161, 95-103. 
doi:10.1016/j.drugalcdep.2016.01.017 
Kader, R., Seedat, S., Govender, R., Koch, J. R., & Parry, C. D. (2014). Hazardous and harmful use 
of alcohol and/or other drugs and health status among South African patients attending HIV 
clinics. AIDS and Behavior, 18, 525-534. doi:10.1007/s10461-013-0587-9 
Kalichman, S. C., Cain, D., & Simbayi, L. C. (2010). Behavioral changes associated with testing 
HIV-positive among sexually transmitted infection clinic patients in Cape Town, South 
Africa. American Journal of Public Health, 100, 714-719. doi:10.2105/AJPH.2009.162602 
Kalichman, S. C., Grebler, T., Amaral, C. M., McNerney, M., White, D., Kalichman, M. O., . . . 
Eaton, L. (2014). Viral suppression and antiretroviral medication adherence among alcohol 




Kee, M. K., Lee, S. Y., Kim, N. Y., Lee, J. S., Kim, J. M., Choi, J. Y., . . . Kim, S. S. (2015). Anxiety 
and depressive symptoms among patients infected with human immunodeficiency virus in 
South Korea. AIDS Care, 27, 1174-1182. doi:10.1080/09540121.2015.1035861 
King, R. M., Vidrine, D. J., Danysh, H. E., Fletcher, F. E., McCurdy, S., Arduino, R. C., & Gritz, E. 
R. (2012). Factors associated with nonadherence to antiretroviral therapy in HIV-positive 
smokers. AIDS Patient Care and STDs, 26, 479-485. doi:10.1089/apc.2012.0070 
Kowalski, S., Colantuoni, E., Lau, B., Keruly, J., McCaul, M. E., Hutton, H. E., . . . Chander, G. 
(2012). Alcohol consumption and CD4 T-cell count response among persons initiating 
antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 61, 455-461. 
doi:10.1097/QAI.0b013e3182712d39 
Kraemer, K. L., McGinnis, K. A., Skanderson, M., Cook, R., Gordon, A., Conigliaro, J., . . . Justice, 
A. C. (2006). Alcohol problems and health care services use in human immunodeficiency 
virus (HIV)-infected and HIV-uninfected veterans. Medical Care, 44, S44-51. 
doi:10.1097/01.mlr.0000223703.91275.78 
L'Akoa R, M., Noubiap, J. J., Fang, Y., Ntone, F. E., & Kuaban, C. (2013). Prevalence and correlates 
of depressive symptoms in HIV-positive patients: A cross-sectional study among newly 
diagnosed patients in Yaounde, Cameroon. BMC Psychiatry, 13, 228. doi:10.1186/1471-
244X-13-228 
Legarth, R. A., Ahlstrom, M. G., Kronborg, G., Larsen, C. S., Pedersen, C., Pedersen, G., . . . Obel, 
N. (2016). Long-term mortality in HIV-infected individuals 50 years or older: A nationwide, 
population-based cohort study. Journal of Acquired Immune Deficiency Syndromes, 71, 213-
218. doi:10.1097/QAI.0000000000000825 
Lima, V. D., Kerr, T., Wood, E., Kozai, T., Salters, K. A., Hogg, R. S., & Montaner, J. S. (2014). 
The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS 
Care, 26, 123-129. doi:10.1080/09540121.2013.804900 
48 
 
Malbergier, A., Amaral, R. A., & Cardoso, L. D. (2015). Alcohol dependence and CD4 cell count: Is 
there a relationship? AIDS Care, 27, 54-58. doi:10.1080/09540121.2014.947235 
Miguez-Burbano, M. J., Lewis, J. E., Fishman, J., Asthana, D., & Malow, R. M. (2009). The 
influence of different types of alcoholic beverages on disrupting highly active antiretroviral 
treatment (HAART) outcome. Alcohol and Alcoholism, 44, 366-371. 
doi:10.1093/alcalc/agp024 
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2010). Preferred reporting items for 
systematic reviews and meta-analyses: The PRISMA statement. International Journal of 
Surgery, 8, 336-341. doi:10.1016/j.ijsu.2010.02.007 
Mugavero, M., Ostermann, J., Whetten, K., Leserman, J., Swartz, M., Stangl, D., & Thielman, N. 
(2006). Barriers to antiretroviral adherence: The importance of depression, abuse, and other 
traumatic events. AIDS Patient Care and STDs, 20, 418-428. doi:10.1089/apc.2006.20.418 
Neblett, R. C., Hutton, H. E., Lau, B., McCaul, M. E., Moore, R. D., & Chander, G. (2011). Alcohol 
consumption among HIV-infected women: Impact on time to antiretroviral therapy and 
survival. Journal of Womens Health, 20, 279-286. doi:10.1089/jwh.2010.2043 
Obel, N., Omland, L. H., Kronborg, G., Larsen, C. S., Pedersen, C., Pedersen, G., . . . Gerstoft, J. 
(2011). Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on 
HAART: A population-based nationwide cohort study. PLoS One, 6, e22698. 
doi:10.1371/journal.pone.0022698 
Ohl, M. E., Perencevich, E., McInnes, D. K., Kim, N., Rimland, D., Akgun, K., . . . Justice, A. 
(2013). Antiretroviral adherence among rural compared to urban veterans with HIV infection 
in the United States. AIDS and Behavior, 17, 174-180. doi:10.1007/s10461-012-0325-8 
Palepu, A., Khan, N. A., Norena, M., Wong, H., Chittock, D. R., & Dodek, P. M. (2008). The role of 
HIV infection and drug and alcohol dependence in hospital mortality among critically ill 
patients. Journal of Critical Care, 23, 275-280. doi:10.1016/j.jcrc.2007.04.001 
49 
 
Parsons, J. T., Rosof, E., & Mustanski, B. (2008). The temporal relationship between alcohol 
consumption and HIV-medication adherence: A multilevel model of direct and moderating 
effects. Health Psycholpgy, 27, 628-637. doi:10.1037/a0012664 
Rotheram-Borus, M. J., Tomlinson, M., Le Roux, I., & Stein, J. A. (2015). Alcohol use, partner 
violence, and depression: A cluster randomized controlled trial among urban South African 
mothers over 3 years. American Journal of Preventive Medicine, 49, 715-725. 
doi:10.1016/j.amepre.2015.05.004 
Samet, J. H., Cheng, D. M., Libman, H., Nunes, D. P., Alperen, J. K., & Saitz, R. (2007). Alcohol 
consumption and HIV disease progression. Journal of Acquired Immune Deficiency 
Syndromes, 46, 194-199. doi:10.1097/QAI.0b013e318142aabb 
Sandra Dearholt, D. D., & Dang, D. (2012). Johns Hopkins nursing evidence based practice model 
and guidelines (2nd ed.). Indianapolis, IN: Sigma Theta Tau International. 
Stein, M., Herman, D. S., Trisvan, E., Pirraglia, P., Engler, P., & Anderson, B. J. (2005). Alcohol use 
and sexual risk behavior among human immunodeficiency virus-positive persons. 
Alcoholism, Clinical and Experimental Research, 29(5), 837-843.  
Sullivan, L. E., Goulet, J. L., Justice, A. C., & Fiellin, D. A. (2011). Alcohol consumption and 
depressive symptoms over time: A longitudinal study of patients with and without HIV 
infection. Drug and Alcohol Dependence, 117, 158-163. 
doi:10.1016/j.drugalcdep.2011.01.014 
Sullivan, L. E., Saitz, R., Cheng, D. M., Libman, H., Nunes, D., & Samet, J. H. (2008). The impact 
of alcohol use on depressive symptoms in human immunodeficiency virus-infected patients. 
Addiction, 103, 1461-1467. doi:10.1111/j.1360-0443.2008.02245.x 
Wetterling, T., Veltrup, C., John, U., & Driessen, M. (2003). Late onset alcoholism. European 
Psychiatry, 18 (3), 112-118.  
50 
 
White, A., & Hingson, R. (2013). The burden of alcohol use: Excessive alcohol consumption and 
related consequences among college students. Alcohol Research: Current Reviews, 35, 201-
218.  
Williams, E. C., Bradley, K. A., Balderson, B. H., McClure, J. B., Grothaus, L., McCoy, K., . . . Catz, 
S. L. (2014). Alcohol and associated characteristics among older persons living with human 
immunodeficiency virus on antiretroviral therapy. Substance Abuse, 35, 245-253. 
doi:10.1080/08897077.2014.890997 
Woolf-King, S. E., Neilands, T. B., Dilworth, S. E., Carrico, A. W., & Johnson, M. O. (2014). 
Alcohol use and HIV disease management: the impact of individual and partner-level alcohol 




















Chapter 3: Associations between Change in Anxiety and Changes in 
Alcohol Use among Women with Human Immunodeficiency Virus 
 
Abstract 
Background: Anxiety and alcohol use are prevalent among women with HIV (WHIV); however, 
their relationship has not been well studied.  
Methods: In a sample of WHIV, we examined the relationship between change in generalized anxiety 
(measured with Hospital Anxiety and Depression, Anxiety Subscale [HADS-A]) and changes in 
alcohol use (measured with Timeline Follow-back) over 12 months using mixed models controlling 
for age, education, race/ethnicity, partner status, viral load, ART, employment status, depression, and 
cocaine use.  
Results: Among 224 WHIV, the prevalence of GAD differed between women with at-risk drinking 
(>7 drinks per week) (28.9%) and those without at-risk drinking (20.2%). The former had higher 
mean depressive symptoms (p=0.047) and anxiety scores (p=0.045) and were more likely to use 
cocaine (p=0.006). There was no significant correlation between change in anxiety and changes in 
alcohol use including binge days, drinking days, and number of drinks per drinking day. However, 
increased cocaine use was associated with increased binge days, drinking days, and number of drinks 
per drinking day (all p≤0.01). Decreased cocaine use was associated with decreased number of drinks 
per drinking day (P<0.01). Decreased depression symptoms were associated with decreased binge 
drinking days (P=0.02) and drinking days (P=0.04).  
Conclusions: Prevalence of GAD is high among WHIV, particularly those with at-risk drinking. For 
these WHIV, changes in cocaine use and depression affect their drinking more than changes in 
anxiety. Clinicians should incorporate assessment of alcohol use, depression, and cocaine status into 
routine HIV care for WHIV and provide them with resources and strategies to effectively manage 
these co-occurring conditions. 
52 
 
Key words: HIV, women, cocaine, depression, alcohol 
INTRODUCTION 
Alcohol use is prevalent among women with human immunodeficiency virus (WHIV). Among 
1123 WHIV in the Women's Interagency HIV Study, 62% reported current alcohol use and 7% 
reported heavy use (Kelso-Chichetto et al., 2017). At-risk alcohol use among women, defined as ≥4 
standard drinks per occasion (one standard drink contains 14 grams of pure alcohol (National 
Institute on Alcohol Abuse and Alcoholism, 2016)) , or average daily drinking of >1 standard drink, 
interferes with entry and retention in the HIV care continuum (Kay et al., 2016)-the steps that 
persons with HIV (PHIV) progress through in order to achieve and maintain viral suppression 
(Braithwaite & Bryant, 2010; Braithwaite et al., 2005; Erickson et al., 2015; Etienne et al., 2010; 
Fatch et al., 2013; Gordon et al., 2006; Kelso-Chichetto et al., 2017; S. Lee et al., 2016; Monroe et 
al., 2016a). These steps include linkage and retention in care, antiretroviral receipt and adherence, 
and viral suppression. Thus, at-risk drinking may increase the risk of developing adverse health 
outcomes among PHIV. This problem may be further compounded among WHIV since women are 
biologically more vulnerable to the effects of alcohol (Cole-Harding & Wilson, 1987; Frezza et al., 
1990) and are more likely to delay alcohol treatment compared with men (Green et al., 2001).  
Anxiety is more prevalent among women compared with men in the general population and 
among WHIV compared with un-infected women (Chander & McCaul, 2003; McLean et al., 2011; 
Saadat et al., 2015; van den Heuvel et al., 2013). HIV-related experiences such as a recent diagnosis 
of HIV (M.-K. Kee et al., 2015) and greater HIV-related stigma (Kamen et al., 2015) have been 
associated with increased anxiety symptoms and emotional distress among PHIV. Demographic 
factors, drug use, and social support are also important predictors of anxiety among PHIV (Catz et 
al., 2002; M. K. Kee et al., 2015). Anxiety may also have both direct and indirect negative effects on 
HIV/AIDS progression (Chander et al., 2006). The reported prevalence of anxiety among WHIV 
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varies widely in the literature (from 1.91% to over 40%) (Goggin et al., 1998; Morrison et al., 2002; 
Niu et al., 2016) depending on methods of assessment of anxiety (Chander et al., 2006), types of 
anxiety assessed, and differences in participants’ characteristics such as social-demographic factors 
and whether HIV is a recent diagnosis. 
Anxiety and alcohol use often co-occur among PHIV (Bing et al., 2001; Chandra et al., 1998; 
Lorra Garey et al., 2015) and both are independently associated with decreased medication adherence 
and viral suppression (Chander et al., 2006). Despite the elevated prevalence of anxiety among 
PLWH, most studies examining the relationship between alcohol use and mental health symptoms 
among PHIV have focused on depression (L. Garey et al., 2015; Havlik et al., 2011; L'Akoa R et al., 
2013; Sullivan et al., 2011; Sullivan et al., 2008; E. C. Williams et al., 2014). Research examining 
the relationship between anxiety and alcohol use among PHIV has been very limited (Chander et al., 
2006; Lorra Garey et al., 2015). Even scarcer are studies that examine this issue targeting WHIV. 
Most existing studies in this area are cross-sectional (Bing et al., 2001; Chandra et al., 1998; Lorra 
Garey et al., 2015). However, because WHIV change their alcohol use patterns over time (Cook et 
al., 2013), existing studies may not have captured the full picture. Understanding the relationship 
between change in anxiety and changes in alcohol use among WHIV may help promote gender-
specific interventions that address both anxiety symptoms and alcohol use, ultimately reducing 
associated adverse outcomes in this population. 
Thus, the purpose of this study is to build upon previous literature by examining associations 
between change in anxiety and changes in alcohol use among WHIV over time. We hypothesized 
that change in anxiety would be positively associated with changes in alcohol use among WHIV. 
METHOD 
Study recruitment   
This was a longitudinal analysis of data from two concurrently recruited cohorts of WHIV. 
One was a randomized controlled trial (RCT) designed to test the effectiveness of a brief alcohol 
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intervention (BI) among 153 WHIV with baseline at-risk drinking (defined as 8 or more drinks/week, 
2 or more binge drinking episodes [defined as 4 or more drinks/occasion] in the past six months, or 
TWEAK score ≥2) who were not currently receiving alcohol treatment (Chander et al., 2015). The 
TWEAK alcohol screening consists of five-questions with a total score of 7 points; a total score ≥2 
indicates at-risk drinking (Russell, 1994). The second cohort was a concurrently recruited sample of 
234 WHIV without at-risk drinking at baseline in care at the same clinic (Barai et al., 2016). The 
parent studies were registered at clinicaltrials.gov: NCT00127231; both studies were approved by the 
Johns Hopkins Medicine Institutional Review Board. 
Participants were recruited between March, 2006 and September, 2010 through several 
methods, including clinic flyers, provider referral, waiting room recruitment, and review of drinking 
data obtained from an audio-computer-assisted-self-interview (ACASI) administered every six 
months to patients who have consented to enroll in the HIV Clinical Cohort (Chander et al., 2015). 
Two parent studies inclusion criteria included women who 1) had a confirmed HIV infection; 2) 
received outpatient care at the Johns Hopkins HIV Clinic; 3) were 18 years of age or older; 4) not 
pregnant; and 5) had no history of psychosis at the time of enrollment. Women in the RCT had visits 
at baseline and three, six, and twelve months post-enrollment; women in the non-at-risk drinking 
cohort had visits at baseline, and six, and twelve months post-enrollment. For the purpose of this 
study, we used data at baseline, six months, and twelve months post-enrollment for both cohorts. 
 
Independent variable: change in anxiety 
Anxiety was measured at each visit using the Hospital Anxiety and Depression Scale Anxiety 
Subscale (HADS-A), which consists of seven questions related to generalized anxiety disorder 
(GAD) (Zigmond & Snaith, 1983). Each question is scored from 0-3 for a maximum score of 21. 
HADS-A scores can be grouped into three clinical categories: normal: 0-7, borderline abnormal: 8-
10, and abnormal: 11-21 (Zigmond & Snaith, 1983). A systematic review reported that Cronbach's 
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alpha for HADS-A varied from 0.68 to 0.93 (mean 0.83) (Bjelland, Dahl, Haug, & Neckelmann, 
2002). Our independent variable, change in anxiety, was measured as a change in the clinical 
category of HADS-A score between two serial visits that were 6 months apart. Changes in anxiety 
were categorized as unchanged anxiety, increased anxiety, and deceased anxiety. 
Dependent Variable: changes in alcohol use 
In this study, alcohol use was measured using the well-validated 90-day timeline follow back 
method (TLFB) (Roy et al., 2008; Sobell et al., 2003). Using this retrospective method, the trained 
interviewer constructed a 90-day calendar that provided daily estimates of the type and amount of 
alcohol use summarized as standard drinks (Annis et al., 1996). Alcohol use over the most recent 90 
days was summarized using three indicators: average number of drinks per drinking day, number of 
drinking days, and number of binge days (> 4 drinks on a single day) in the 90 days preceding each 
study visit.  
 
Additional covariates of interest 
Additional covariates of interest were selected based on previous literature (Samet et al., 
2007). Of those covariates, socio-demographic factors included age (continuous variable), 
cohabitating partner status (currently living with a partner or not), education (years completed, 
continuous variable), race/ethnicity (self-identified as African-American/Black or others [including 
Caucasians, Hispanic, Alaskan Native, Asian, American Indian or refused to answer]). Age, race, 
domestic cohabitating partner status, education, antiretroviral therapy (ART) use (current use or not) 
were obtained through an Audio Computer Assisted Self Interview (ACASI) at baseline visit. 
Cocaine use was obtained from the TLFB at each visit. Depression was assessed via ACASI using 
the Beck Depression Inventory (BDI), which is a 21-item self-report inventory (Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961). BDI score can be grouped into four clinical categories: 0-9 
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indicating minimal depression, 10-18 mild depression, 19-29 moderate depression, and 30-63 severe 
depression. Change in depression was measured as a change in the clinical category of depression 
between two visits that were 6 months apart and contained three possible levels: increased 
depression, unchanged depression, and decreased depression. Change in cocaine use was grouped 
into three possible levels: use to no use, unchanged, and no use to use between two serial visits that 
were 6 months apart. Finally, we combined ART use and viral load into a single covariate with three 
possible levels: detectable viral load without ART, detectable viral load with ART, and undetectable 
viral load with or without ART. Viral load was drawn on the day of the baseline visit if there had 
been none in the medical record in the 30 days prior to baseline visit.  
 
Analysis 
To be included in this analysis, participants were required to 1) have reported at least one 
drinking episode at one of their visits; 2) have at least two serial study visits that were six months 
apart; and 3) have complete data on the covariates selected for analysis. Participants not meeting the 
above criteria were dropped (n=163). To examine the association between change in anxiety and 
changes in alcohol use, we constructed three mixed-effects models with dependent variables being 
change in average number of drinks per drinking day, change in number of drinking days, and 
change in number of binge days over the past 90 days. Our independent variable was change in 
anxiety. We adjusted all three models for the following time-fixed covariates: age, cohabitating 
partner status, education, race, and a combined covariate on whether a person is currently taking 
ART, and whether a person’s viral load is detectable. We also adjusted for the time-varying 
covariates of cocaine use and depression. We used generalized estimation equation to account for 
repeated measures of the same individual. All Analyses were conducted using SAS software (version 





A total of 387 women were recruited into the two cohorts, 153 from RCT and 234 from the 
observational cohort. During analysis, a total of 163 were excluded including 125 nondrinkers, 7 with 
missing values, 31 who did not have two serial visits that were six months apart. The final study 
population consisted of 224 WHIV. There were no differences in socio-demographic characteristics 
between the included and excluded participants. Among the 224 women, 216 completed all three 
study visits and were included in the assessments of changes between the baseline and six-month 
visit, as well as between the six-month and 12-month visit. Eight women participated in two study 
visits and were included in one assessment of change between either the baseline and six-month visit 
or the six-month and 12-month visit. Out of the total of 440 intervals, at-risk drinkers contributed 263 
study intervals and non-at-risk drinkers contributed 177 study intervals. Characteristics of the study 
population, stratified by baseline drinking status, were presented in Table 1. The 224 study 
participants were predominantly African-American, aged around 45 years old, and most completed 
less than a high school education (<12 years). They reported an average of 14.82 binge days (SD= 
24.44), 19.50 drinking days (26.12), and 6.20 drinks (SD=7.27) on a drinking day in the past 90 days 
at baseline visit. Participants with at-risk drinking at baseline had higher mean BDI depression score 
(p=0.047) and HADS-A anxiety score (p=0.045) and were more likely to use cocaine (p=0.006). 
However, there was no difference in the distribution of the depression or anxiety clinical categories 
between the two baseline drinking groups (p=0.39, p=0.33).  
Change in Anxiety 
Among the 263 intervals with at-risk drinking at baseline, anxiety category decreased in 46%, 
increased in 38%, and remained unchanged in 15%. Among the 177 intervals with non-at-risk 
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drinking at baseline, anxiety category decreased in 46%, increased in 40%, and remained unchanged 
in 14% of the intervals. 
Change in Alcohol Use 
Among the 263 intervals with at-risk drinking at baseline, binge days decreased in 59%, 
increased in 30%, and remained unchanged in 11% of the intervals (median change of binge days in 
one interval = -2 days, interquartile range [IQR]: -10.55, 1.82). Average number of drinks per 
drinking day decreased in 59%, increased in 34%, and remained unchanged in 7% of the intervals 
(median change of drinks per drinking day in one interval= -0.88 drinks, IQR: - 4.07, 1.03). Drinking 
days decreased in 58%, increased in 33%, and remained unchanged in 9% of the intervals (median 
change of drinking days in one interval= -2 days, IQR: -13, 2).  
Among the 177 intervals with non-at-risk drinking at baseline, binge days decreased in 5%, 
increased in 24%, and remained unchanged in 71% of the intervals (median change of binge days in 
one interval =0 days, IQR: 0, 0). Drinks per drinking day decreased in 34%, increased in 47%, and 
remained unchanged in 19% of the intervals (median change of drinks per drinking day in one 
interval=0 drinks, IQR: -0.99, 1.89). Drinking days decreased in 34%, increased in 41%, and 
remained unchanged in 25% of the intervals (median change of drinking days in one interval =0 
days, IQR: -1, 2). 
Associations between change in anxiety and change in alcohol use  
Binge Drinking Days  
Based on multivariable analysis, there was no significant correlation between change in 
anxiety and change in binge drinking days (Table 2). However, a change in cocaine use from no use 
to use between two serial visits was associated with an increase of 9.90 binge drinking days over 90 
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days compared to no change in cocaine use (p<0.01). Moreover, if a participant transitioned into a 
lower depression category(s) between two serial visits, binge drinking days over 90 days decreased 
by 5.65 days (p=0.02). 
Drinking Days 
Based on multivariable analysis, there was no significant correlation between change in 
anxiety and change in drinking days (Table 3). A change in cocaine use from no use to use between 
two serial visits was associated with an increase of 10.81 drinking days over 90 days compared to no 
change in cocaine use (p<0.01). Moreover, if a participant transitioned into a lower depression 
category(s) between two serial visits, drinking days over 90 days decreased by 5.02 days (p=0.04). 
Drinks Per Drinking Day 
Based on multivariable analysis, there was no significant correlation between change in 
anxiety and change in average number of drinks per drinking day (Table 4). A change in cocaine use 
from use to no use between two serial visits, compared to no change in cocaine use, was associated 
with a decrease of average 2.75 drinks per drinking day over 90 days (p<0.01). A change in cocaine 
use from no use to use between two serial visits, compared to no change in cocaine use, was 
associated with an increase of average 2.82 drinks per drinking day over 90 days (p=0.01). 
DISCUSSION 
In this sample of 224 WHIV, baseline GAD measured by HADS-A scores were higher among 
at-risk compared to non-at-risk drinkers. In line with this, the overall prevalence of GAD at baseline 
was 25%, with a higher proportion of at-risk drinkers experiencing GAD (29%) compared to non-at-
risk drinkers (20%). Contrary to our hypothesis, we did not find a significant association between 
change in GAD and change in granular measures of alcohol use including binge days, drinking days, 
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and average number of drinks per drinking day. We did find, however, that increase in cocaine use 
was associated with increased binge days, drinking days, and average number of drinks per drinking 
day. Decrease in cocaine use was associated with decreased average number of drinks per drinking 
day. Decreased depression symptoms were associated with decreased binge drinking days and 
drinking days. These findings suggest that, in this sample of predominantly black WHIV, change in 
GAD was not associated with change of alcohol use; cocaine use and depressive symptoms play a 
greater role in drinking changes.  
Our finding that baseline anxiety scores were higher in at-risk compared with non-at-risk 
drinkers is in line with other cross-sectional studies which found that anxiety (anxiety affect, panic, 
and social anxiety) is positively associated with alcohol use among PHIV (Lorra Garey et al., 2015; 
M.-K. Kee et al., 2015) as well as in the general population (Kushner, Abrams, & Borchardt, 2000; 
McCaul, Hutton, Stephens, Xu, & Wand, 2017; Smith et al., 2006). Potential reasons explaining the 
association between the two include the self-medication hypothesis and cause-consequence 
hypothesis (Merikangas, Stevens, & Fenton, 1996). According to the self-medication hypothesis, 
people drink to cope with anxiety, which in turn escalates their alcohol use via negative 
reinforcement (Quitkin, Rifkin, Kaplan, & Klein, 1972). Based on the cause-consequence hypothesis, 
anxiety is a consequence of chronic substance use and/or withdrawal syndrome (George, Nutt, 
Dwyer, & Linnoila, 1990). Importantly, it appears that the relationship 
between alcohol problems and anxiety varies across different types of anxiety disorders (Brandt et 
al., 2017; Kushner et al., 2000). For example, results of Catchment Area Survey indicated that 
alcohol dependence was associated with nearly all types of anxiety disorders except for simple 
phobia (Himle & Hill, 1991). Thus, much remains unknown about the relationship between different 
types of anxiety and alcohol use for PHIV, in particular WHIV.  
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Although we observed the expected cross-sectional differences in GAD as a function of 
alcohol use at baseline, we did not observe the hypothesized relationship between change in anxiety 
symptoms and change in alcohol use. Most women in our study had at-risk drinking at baseline 
(60.3%), which over represented the true prevalence of alcohol use among WHIV. These women 
may have had problematic anxiety and alcohol use for so long that the relatively short-term 
relationship between the two issues was obscured by their chronicity. In addition, these women faced 
other complexities in life including lack of social support and poor economic well-being which may 
have overwhelmed the short-term relationship between anxiety and alcohol use. Nevertheless, we 
believe that our study make a unique contribution to the literature given the fact that most existing 
studies were mostly cross-sectional, did not adopt detailed measures of drinking, and did not evaluate 
changes (Bing et al., 2001; Chandra et al., 1998; Lorra Garey et al., 2015; Smith et al., 2006) even 
though people’s drinking change over time (Cook et al., 2013) .  
Our study yielded some other important findings. Our study found that if a WHIV’s depression 
category decreased between two 6-month apart visits, binge days and drinking days would decrease. 
This finding was consistent those of previous studies (L. Garey et al., 2015; Havlik et al., 2011; M. 
K. Kee et al., 2015; L'Akoa R et al., 2013; Sullivan et al., 2011; Sullivan et al., 2008; Emily C. 
Williams et al., 2014) and suggests that if WHIV have reduced depressive symptoms, they may not 
only decrease depression-associated outcomes such as medication nonadherence (Magidson, Saal, 
Nel, Remmert, & Kagee, 2017) and decreased immune functions (Leserman, 2003) but also binge 
day, drinking days, and their associated outcomes. The mechanisms between depression and alcohol 
use remains unclear but a meta-study suggested a causal mechanism in which drinking increases the 
risk of depression by inducing neurophysiological and metabolic changes in a person. Further studies 
are needed to clarify this link (Boden & Fergusson, 2011).  
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Moreover, our study found that for all three indicators of alcohol use, change in cocaine use 
from no use to use was associated with increased alcohol use. Change in cocaine use from use to no 
use was associated with decreased average number of drinks per drinking day. This finding is 
supported by several studies where researchers demonstrated that cocaine use was positively 
associated with alcohol use among PHIV (Chander et al., 2006; Crane et al., 2017) as well as the 
general population (Pennings, Leccese, & Wolff, 2002). Prior research suggests that people used 
cocaine and alcohol together to intensify the high feeling of cocaine and to reduce the feeling of 
drunkenness (Pennings et al., 2002). Among our participants, cocaine use was prevalent (26%), 
especially among those with at-risk drinking at baseline (33.3%). This finding warrants our attention 
because of the greater-than-additive effects of cocaine and alcohol taken together. The combined use 
of alcohol and cocaine can exacerbate the negative biological and behavioral consequences compared 
to the use of either alone, including cardiotoxicity, violent thoughts, and threats (Pennings et al., 
2002). Furthermore, for PHIV, cocaine use is associated with accelerated HIV disease progression, 
decreased medication adherence, and increased mortality (Baum et al., 2009; Vittinghoff et al., 
2001). Of particular interest, our study indicates that among WHIV, for alcohol use and cocaine use, 
an increase in one may lead to an increase in the other substance. Thus, we should consider targeting 
both substances when developing substance prevention/reduction interventions. Although alcohol 
screening and brief interventions have been shown to be effective in reducing drinking for WHIV 
(Chander et al., 2015) and uninfected women with at-risk drinking (Manwell, Fleming, Mundt, 
Stauffacher, & Barry, 2000; O'Donnell et al., 2014), our study indicates that it is important to 
develop integrated alcohol and cocaine prevention/reduction interventions targeting WHIV as 
increasing cocaine use may lead to not only cocaine-associated outcomes but also increases in 
alcohol use and alcohol-associated adverse outcomes.  
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So far as we know, this is the first longitudinal study to examine GAD and alcohol use among 
WHIV. Research on anxiety targeting PHIV is limited despite of its high importance given the 
prevalence of the problem and its negative physical and emotional effects on this population (Brandt 
et al., 2017; Chander et al., 2006). Thus, our study targeted a much-needed area. There are several 
other strengths to this study including rigorous assessment and granular measures of alcohol use in an 
urban sample of WHIV. It’s important to look at alcohol use using different indicators because their 
associated health risks may differ. For example, binge drinking is associated with over half of alcohol 
associated deaths in the general population in the US between 2002-2005 (Kanny et al., 2013). In 
addition, women are biologically more vulnerable to the negative effects of alcohol use than men and 
are less likely to receive and more likely to delay alcohol treatment than men (Green et al., 2001). 
The participants in this study mainly consisted of middle-aged black WHIV, most of whom 
completed less than high school education, and reported a low income. They are a marginalized 
group in our society but are overrepresented among WHIV (Duarte, Parada, & Souza Ldo, 2014; 
L'Akoa R et al., 2013). For WHIV, alcohol use may further contribute to HIV-related health 
disparities after diagnosis (Myers et al., 2009), negatively affect their use of available HIV 
prevention and treatment resources (Hader, Smith, Moore, & Holmberg, 2001), and lead to negative 
social interactions (Myers et al., 2009). However, research studies have understudied WHIV, 
especially African-American WHIV (DeJong & Battistin, 2015; Myers et al., 2009). Last but not the 
least, demographic (age, race, employment status, domestic partner status), behavioral (ART use, 
cocaine use) and psychosocial factors (depression) were controlled in the analysis to yield the 
independent effects of changes of anxiety on changes of alcohol use.  
Despite of the merits mentioned above, this study has some limitations. First, alcohol use was 
measured by self-reported calendar method. While this method has been demonstrated to be reliable 
and is widely used (Carpenter, Mayer, Fisher, Desai, & Durand, 1989), participants’ self-report may 
64 
 
underestimate their drinking. Indeed, the latest development in biomarkers, such as 
phosphatidylethanol (PEth) in blood offers a more advanced method to assess the accuracy of self-
reported alcohol use (Walther et al., 2015). Future studies can use biomarkers in conjunction with 
traditional self-report approaches to assess the relationship between anxiety and alcohol use more 
accurately. Moreover, in this study, we only assessed GAD using HADS-A and thus cannot 
generalize our findings to other types of anxiety. In addition, in the parent study, WHIV with at-risk 
drinking were purposefully over-sampled and thus our study population did not reflect the true 
prevalence of alcohol use among WHIV. Finally, statistically, with limited number of visit we were 
not able to establish models that infer causality by creating lagging of time. Future longitudinal 
studies assessing different types of anxiety, containing a more representative sample, using the latest 
biomarkers to evaluate alcohol use, and having multiple time intervals to assess changes with lagging 
are warranted.  
The implications for clinical practice based on our findings are as follows: Although we did 
not detect a relationship between change in anxiety and change in alcohol use, we have other relevant 
findings that demonstrated the risks of cocaine use and depression on alcohol use among WHIV. 
Clinicians should assess depression status and cocaine use status for WHIV and provide them with 
resources and strategies to manage their depression and cocaine use. Clinicians should inform WHIV 
that if they increase cocaine or alcohol, they would possibly increase the use of the other substances 











































Table 2. Mixed effect model examining the association between changes in anxiety and 
changes in average number of binge days among WHIV 
Predictor Estimate SE(B) T Value Pr>|t| 
Intercept 1.75 7.39 0.24 0.81 











Age (years)1 45.79 (8.17) 46.74 (8.76) 45.16 (7.72) 0.17 
Education (years)1 11.40 (2.08) 11.62 (2.26) 11.26 (1.95) 0.22 
African-American2             186 (83.0%) 73 (82.0%)   113 (83.7%)  0.74 




 120 (88.9%) 
 
0.44 
Viral load and ART 
Detectable viral load& no 
ART2 
Undetectable viral load with 
/without ART2 
Reference: Detectable viral 
























Unemployed2 189 (84.3%) 73 (80.1%) 116 (85.9%) 0.43 




7.37 (4.62) 6.58 (5.02) 7.89 (4.28) 0.045 
125 (55.8%) 54 (60.7%) 71 (52.6%)) 0.33 
42 (18.8%) 17 (19.1%) 25 (18.5%) 
57 (25.4%) 18 (20.2%) 39 (28.9%) 
Average number of binge 
days in the past 90 days1, 3 
14.82 (24.44)  0.00 (0.00) 24.59 (27.42) <0.01 
Average number of drinking 
days in the past 90 days1 
19.50 (26.12) 2.87 (6.34) 30.45 (28.36) <0.01 
Average number of drinks on 
a drinking day in the past 90 
days1 
6.20 (7.27) 1.06 (1.13) 9.58 (7.63) <0.01 





9.81 (8.80) 8.37 (8.90) 10.76 (8.64) 0.047 
127 (56.7%) 56 (25.0%) 71 (31.7%) 0.39 
54 (24.1%) 20 (8.9%) 34 (15.2%) 
38 (17.0%) 11 (4.9%) 27 (12.0%) 
5 (2.2%) 2 (0.9%) 3 (1.3%) 
Use cocaine2 60 (26.8%) 15 (16.9%) 45 (33.3%) 0.006 
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Age (years) -0.14 0.11 -1.27 0.21 
Domestic partner 
Living with a partner 













Change of cocaine use 
Use to no use  
No use to use  









9.90 3.38 2.92 <0.01 
0 - - - 
Education (years) 0.24 0.44 0.55 0.58 
Race 
African Americans 

















Reference: no change 
    
-2.56 2.38 -1.07 0.28 
3.49 2.55 1.37 0.17 
0 - - - 




Reference: no change 
    
-5.65 2.30 -2.46 0.02 
1.27 2.80 0.45 0.65 
0 - - - 
Viral load and ART 
Detectable viral load& 
no ART2 
Undetectable viral load 
with /without ART2 
Reference: detectable 









0.38 2.19 0.17 0.86 
0 - - - 





Table 3. Mixed effect model examining the association between changes in anxiety and 
changes in average number of drinking days among WHIV 
Predictor Estimate SE(B) T Value Pr>|t| 
Intercept -0.48 7.93 -0.06 0.95 
Age (years) -0.16 0.12 -1.33 0.18 
Domestic partner 
Living with a partner 















Change of cocaine use 
Use to no use  
No use to use  









10.81 3.63 2.98 <0.01 
0 - - - 
Education (years) 0.55 0.47 1.16 0.25 
Race 
African Americans 

















Reference: no change 
    
-2.20 2.56 -0.86 0.39 
1.27 2.74 0.47 0.64 
0 - - - 




Reference: no change 
    
-5.02 2.47 -2.03 0.04 
3.71 3.00 1.24 0.22 
0 - - - 
Viral load and ART 
Detectable viral load& 
no ART2 
Undetectable viral load 
with /without ART2 
Reference: detectable 









-0.59 2.34 -0.25 0.80 
0 - - - 





Table 4. Mixed effect model examining the association between changes in anxiety and 
changes in average number of drinks per drinking day among WHIV 
Predictor Estimate SE(B) T Value Pr>|t| 
Intercept 2.03 2.42 0.84 0.40 
Age (years) -0.02 0.04 -0.44 0.66 
Domestic partner 
Living with a partner 













Change of cocaine use 
Use to no use  
No use to use  









2.82 1.11 2.54 0.01 
0 - - - 






















Reference: no change 
    
-0.76 0.78 -0.97 0.33 
0.68 0.83 0.81 0.42 
0 - - - 




Reference: no change 
    
0.85 0.75 -1.13 0.26 
-0.77 0.91 -0.84 0.40 
0 - - - 
Viral load and ART 
Detectable viral load& 
no ART2 
Undetectable viral load 
with /without ART2 
Reference: detectable 









0.33 0.72 0.45 0.65 
0 - - - 
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Chapter 4: The Relationship between Alcohol Use, Anxiety, and 
Depression and Retrospective Attendance of Primary Care Visits among 
Women with Human Immunodeficiency Virus 
 
Abstract 
Background: Retention in care (RIC) is important for women with human immunodeficiency virus 
(WHIV) to achieve desired health outcomes. In this study, we sought to determine the associations 
between alcohol use, anxiety, and depression and RIC among WHIV. 
Methods: Alcohol use was assessed using the Timeline Follow-back; measures included number of 
standard drinks per drinking days, drinking days, and binge drinking days. Anxiety symptoms were 
assessed with Hospital Anxiety and Depression, Anxiety Subscale (HADS-A); scores were 
categorized into three severity levels. Depressive symptoms were assessed with Beck Depression 
Inventory (BDI); scores were categorized into four severity levels. Primary care visits over the prior 
twelve months were collected from clinic registration records and classified as “show” or “no show”. 
We used three logistic mixed models, each with a single alcohol use measure (drinks per drinking 
day, binge drinking days, or drinking days) to examine the associations between alcohol use, anxiety, 
depression and attendance of primary care visits, adjusting for age, race/ethnicity, education, 
domestic partner status, viral load, cocaine use, and antiretroviral therapy status (ART). 
Results: Among 364 WHIV, mean attendance of primary care visits was 63.9%. Every one-day 
increase in binge drinking days (Odds ratio [OR]=0.99, 95% CI 0.99,1.00) or drinking days 
(OR=0.99, 95% CI 0.99, 1.00) was associated with decreased odds of attending primary care 
visits(p=0.02). Moderate/severe anxiety scores, compared to normal anxiety scores, were associated 
with decreased odds of attending primary care visits (OR=0.69, 95% CI 0.50, 0.97). Depressive 
symptoms were not significantly associated with retention in care. In all three models, increasing age 
and undetectable viral load (compared to detectable viral load) were associated with increased odds 
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of attending primary care visits. Cocaine use (compared to no use) was associated with decreased 
odds of attending primary care visits.  
Conclusions: Our findings indicate that identifying and treating WHIV with alcohol use especially 
binge drinking as well as cocaine use and/or moderate/severe anxiety could potentially improve their 
RIC. 
Key words: Women, HIV, anxiety, alcohol, retention in care, cocaine 
INTRODUCTION 
Engagement and retention in care are associated with suppressed viral load (Robbins et al., 
2007; Sethi, Celentano, Gange, Moore, & Gallant, 2003) and decreased likelihood of death 
(Giordano et al., 2007; Lee et al., 2013; Mugavero et al., 2009) among people with HIV (PHIV), and 
thus are critical steps in the HIV Care Continuum (Kay, Batey, & Mugavero, 2016). Retention in 
care (RIC) is defined in different ways and includes attending two medical visits at least 90 days 
apart (Institute of Medicine [IoM] index and the Department of Health and Human Services [DHHS] 
indicator (Rebeiro et al., 2014)), missed clinical visits (Mugavero et al., 2014) or both (Horstmann, 
Brown, Islam, Buck, & Agins, 2010). Although the IoM/DHHS definition often serves as a national 
benchmark and is required to be reported by certain HIV services agencies (Committee on Review 
Data Systems for Monitoring HIV Care), if we solely rely on this definition to examine RIC, we may 
undercount the number of missed visits and their consequences even among persons who are 
classified as being retained. Prior studies found that missed clinical visits are exceedingly common 
even among PHIV who are classified as retained and if we further evaluate missed clinic visits 
among those individuals, we can obtain additional independent prognostic information about them 
such as risk of all-cause mortality (Mugavero et al., 2014). 
In the US, a significant proportion of PHIV have poor RIC (Mugavero, Amico, Horn, & 
Thompson, 2013; Robbins et al., 2007), even among those attending Veteran Affairs Hospitals or 
clinics where few financial barriers exist (Giordano et al., 2007). Prevalence of non-RIC in PHIV 
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varies widely among published studies, ranging from 11% to 42% depending on socio-demographic, 
behavioral, and health profiles of the study population and approaches to measuring RIC (Giordano 
et al., 2007; Monroe et al., 2016; Robbins et al., 2007; Yang, Yan, Liu, Huang, & Long, 2015). Poor 
RIC is associated with socio-cultural, economic, and health factors (Tiruneh, Galarraga, Genberg, & 
Wilson, 2016). According to a national cohort study of 2,619 US veterans, being black, younger age, 
high CD4 cell count (>350 cells/μL), and illicit drug use predict poor RIC (Giordano, Hartman, 
Gifford, Backus, & Morgan, 2009). In addition, in qualitative work, researchers identified fear of 
stigma, care dissatisfaction, and economic constraints to be factors that impeded RIC among PHIV 
(Tiruneh et al., 2016).  
At-risk drinking is another concern for PHIV. For the general population, it is defined as 
drinking on average >2 standard drinks (one drink contains 14 grams of pure alcohol) per day for 
men, and >1 drink per day for women (Alcoholism, 2016). For PHIV, they may face increased risk of 
developing adverse outcomes even at lower levels of consumption (Bonacini, 2011). Numerous 
studies demonstrate an association between alcohol use and medication nonadherence (Beer & 
Skarbinski, 2014; Braithwaite et al., 2005; Carrico, Woolf-King, Neilands, Dilworth, & Johnson, 
2014; Chitsaz et al., 2013; Conen et al., 2009; Herrmann et al., 2012; Holmes, Bilker, Wang, 
Chapman, & Gross, 2007; Lima et al., 2014; Marks King et al., 2012; Ohl et al., 2013; Parsons, 
Rosof, & Mustanski, 2008; Williams et al., 2014; Woolf-King, Neilands, Dilworth, Carrico, & 
Johnson, 2014) and delayed treatment initiation (Koirala et al., 2017) among PHIV. However, fewer 
studies have examined the association between alcohol use on and attendance of primary care visits, 
particularly among women with HIV (WHIV) (Koirala et al., 2017; Mugavero et al., 2013). It is 
especially important to look at this issue among WHIV because 1) drinking is more prevalent among 
WHIV than women not with HIV (Neblett et al., 2011); 2) women compared with men are less likely 
to disclose drinking to primary care providers (Cucciare et al., 2016); 3) women are more vulnerable 
to the effects of alcohol than men due to decreased first-pass metabolism of alcohol and a lower 
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proportion of water in their body (Cole-Harding & Wilson, 1987; Frezza et al., 1990); and 4) women 
are more likely to delay treatment for alcohol use disorder compared with men (Green, Freeborn, & 
Polen, 2001).  
Another issue that needs to be specially attended to in WHIV is mental health symptoms such 
as anxiety and depression which are more prevalent among women compared with men in the 
general population and among PHIV (Chander & McCaul, 2003; McLean, Asnaani, Litz, & 
Hofmann, 2011; Saadat, Behboodi, & Saadat, 2015; van den Heuvel et al., 2013). These symptoms 
may negatively affect HIV-related outcomes in this population (Chander, Himelhoch, & Moore, 
2006). Although there is extensive literature demonstrating the negative relationship between mental 
health symptoms and medication adherence (Magidson, Saal, Nel, Remmert, & Kagee, 2017), there 
have been fewer studies examining the relationship between mental health symptoms and attendance 
of primary care visits among PHIV, even fewer that exclusively targeted WHIV (Zuniga, Yoo-Jeong, 
Dai, Guo, & Waldrop-Valverde, 2016). 
Understanding the association between alcohol use and mental health symptoms and 
attendance of primary care visits among WHIV is important given the impact of those issues on 
health outcomes of WHIV. Thus, the purpose of this study was to build upon previous literature by 
examining the relationships between alcohol use, anxiety, and depression, and likelihood of attending 
primary care visits among WLHV. We hypothesized that the factors above would be negatively 
associated with attendance of primary care visits among WHIV. 
METHODS 
Study recruitment  
Data used in this study came from two concurrently recruited cohorts of WHIV. One was a 
randomized controlled trial (RCT) designed to test the effectiveness of a brief alcohol intervention 
(BI) among 153 WHIV with baseline at-risk drinking (defined as 8 or more drinks/week, 2 or more 
binge drinking episodes [defined as 4 or more drinks/occasion] in the past six months, or TWEAK 
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score ≥2) who were not currently receiving alcohol treatment (Chander, Hutton, Lau, Xu, & McCaul, 
2015). The TWEAK alcohol screening consists of five-questions with a total score of 7 points; a total 
score ≥2 indicates at-risk drinking (Russell, 1994). The second cohort was a concurrently recruited 
sample of 234 WHIV without at-risk drinking at baseline in care at the same clinic (Barai et al., 
2016). The parent studies were registered at clinicaltrials.gov: NCT00127231; both studies were 
approved by the Johns Hopkins Medicine Institutional Review Board. 
Participants were recruited between March, 2006 and September, 2010 through clinic flyers, 
provider referral, waiting room recruitment, and review of drinking data obtained from an audio-
computer-assisted-self-interview (ACASI) routinely administered to patients enrolled in the HIV 
Clinical Cohort every six months (Chander et al., 2015). Study inclusion criteria included women 
who 1) had a confirmed HIV infection; 2) received outpatient care at the Johns Hopkins HIV Clinic; 
3) were 18 years of age or older; 4) were not receiving treatment for an alcohol use disorder (AUD); 
5) were not pregnant; and 6) had no history of psychosis at the time of enrollment.  
 
Independent variable: Alcohol use at baseline  
In this study, alcohol use was measured using the well-validated 90-day timeline follow back 
(TLFB) (Roy et al., 2008; Sobell et al., 2003) at participants’ baseline visit. Using this retrospective 
method, the trained interviewer constructed a 90-day calendar that provided daily estimates of the 
type and amount of drinking which were summarized as standard drinks (Annis et al., 1996). Alcohol 
use was then converted into three measures, including average number of drinks per drinking day, 
number of drinking days, and number of binge days in the past 90 days preceding a participant’s 
baseline visit.  
 
Independent variable: Anxiety and depression at baseline 
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Anxiety was measured using the Hospital Anxiety and Depression Scale Anxiety Subscale 
(HADS-A), which consists of seven questions related to generalized anxiety disorder (GAD) 
(Zigmond & Snaith, 1983) with a maximum score of 21. HADS-A scores would then be grouped into 
three clinical categories: normal (0-7), mild (8-10), and moderate/severe (11-21) (Zigmond & Snaith, 
1983). A systematic review reported that Cronbach's alpha for HADS-A varied between 0.68 and 
0.93 (mean 0.83) (Bjelland, Dahl, Haug, & Neckelmann, 2002). Depression was measured using the 
Beck Depression Inventory (BDI), which is a 21-item self-report inventory (Beck, Ward, Mendelson, 
Mock, & Erbaugh, 1961) with a maximum score of 63. BDI total score was then categorized into 
four clinical depression categories: minimal (0-9), mild (10-18), moderate (19-29), and severe (30-
63).  
Dependent variable: Attendance of primary care visits over 12 months prior to baseline 
In this study, we used clinic registration data to capture primary care visit attendance over the 12 
months prior to participants’ baseline study visit. Visits were classified as “show”, “no show” or 
“cancelled”. Cancelled visits were excluded from this analysis, and our outcome was operationalized 
as a binary variable (“show” or “no show”). 
 
Additional covariates of interest 
Additional covariates included age (continuous variable), education (years completed, 
continuous variable), cohabitating partner status (currently living with a partner or not), 
race/ethnicity (self-identified as African-American/Black or others [including Caucasians, Hispanic, 
Alaskan Native, Asian, American Indian or refused to answer]), and whether a person used cocaine 
(yes or no). We combined use of antiretroviral therapy (ART) and viral load into a single covariate 
with three nominal levels (detectable viral load without ART, undetectable viral load with/without 
ART, and detectable viral load with ART). Race, domestic cohabitating partner status, ART use, and 
education were obtained through ACASI at baseline visit. Cocaine use was obtained using the 90-day 
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TLFB at baseline visit. Viral load was drawn on the day of the baseline visit if there had been none in 
the medical record in the 30 days prior to baseline visit. 
 
Statistical analysis 
To be included in this analysis, participants were required to have complete data on the 
variables selected for analysis. Participants not meeting the above criteria were dropped (N=23). To 
examine the association of baseline alcohol use, anxiety, and depression on attendance of primary 
care visits over prior 12 months, we constructed three logistic mixed models, with independent 
variables being 1) average number of drinks per drinking day, 2) number of drinking days, and 3) 
number of binge days over the past 90 days prior to baseline visit respectively. Our dependent 
variable primary care visit attendance was operationalized as a binary distributed outcome (“1” for 
show and “0” for no show). Only visits within 365 days prior to baseline were included into analysis. 
Depressive and anxiety symptoms were included in all the three models. We adjusted the three 
models for the following time-fixed covariates: age, cohabitating partner status, education, race, and 
a combined covariate on ART and viral load detectable, and whether a person used cocaine. We used 
generalized estimation equation to account for repeated visits of the same individuals. All Analyses 




A total of 387 women were recruited into the two cohorts, 153 from RCT and 234 from the 
observational cohort. During analysis, 23 were excluded due to missing information. The final study 
population consisted of 364 WHIV. There were no socio-demographic differences between the 
included and excluded participants. Characteristics of the study population are presented in Table 1. 
Participants were predominantly African-American, age around 46 years old, had an average 
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education of 11.44 years, and were living without a partner (87.6%). Twenty two percent of them 
used cocaine and 23.6% of them had moderate-to-severe levels of anxiety. They reported an average 
of 10.25 binge days, 13.35 drinking days, and 4.43 drinks on a drinking day in the past 90 days 
preceding baseline visit. On average, they had 8.47 scheduled visits over 12 months and attended 
63.9% of them. 
 
Associations between alcohol use, anxiety, and depression and attendance of primary care visits 
Drinks per drinking day 
In multivariable analysis, there were no significant relationships between drinks per drinking 
day and depression symptoms and attendance of primary care visits (Table 2, Model 1). However, 
moderate/severe anxiety, compared to normal anxiety, was associated with decreased odds of 
attending primary care visits (Odds ratio [OR]=0.69, 95% CI 0.50,0.97). Every one-year increase in 
age was associated with increased odds of attending primary care visits (OR=1.02, 95% CI 1.01, 
1.04). Undetectable viral load, compared to detectable viral load, was associated with increased odds 
of attending primary care visits (OR=1.64, 95% CI 1.20, 2.26). Cocaine use, compared to no use, was 
associated with decreased odds of attending primary care visits (OR=0.57, 95% CI 0.43, 0.75) 
 
Binge drinking days  
In multivariable analysis, every one-day increase in binge drinking days was associated with 
decreased odds of attending primary care visits (OR=0.99, 95% CI 0.99, 1.00) (Table 2, Model 2). 
Moderate/severe anxiety, compared to normal anxiety, was associated with decreased odds of 
attending primary care visits (OR=0.69, 95% CI 0.49, 0.96). Depression was not associated with 
odds of attending primary care visits. Moreover, every one-year increase in age was associated with 
increased odds of attending primary care visits (OR=1.02, 95% CI 1.01-1.04). Undetectable viral 
load, compared to detectable viral load, was associated with increased odds of attending primary care 
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visits (OR=1.61, 95% CI 1.17, 2.21). Cocaine use, compared to no use, was associated with 
decreased odds of attending primary care visits (OR=0.57, 95% CI 0.43, 0.75). 
 
Drinking days 
In multivariable analysis, every one-day increase in drinking days was associated with 
decreased odds of attending primary care visits (OR=0.99, 95% CI 0.99, 1.00) (Table 2, Model 3). 
Moderate/severe anxiety, compared to normal anxiety was associated with decreased odds of 
attending primary care visits (OR=0.69, 95% CI 0.50, 0.96). Depression was not associated with 
odds of attending primary care visits. Moreover, every one-year increase in age was associated with 
increased odds of attending primary care visits (OR=1.02, 95% CI 1.01-1.04). Undetectable viral 
load, compared to detectable viral load, was associated with increased odds of attending primary care 
visits (OR=1.59, 95% CI 1.15, 2.18). Cocaine use, compared to no use, was associated with 
decreased odds of attending primary care visits (OR=0.57, 95% CI 0.43, 0.75). 
 
DISCUSSION 
In this sample of 364 WHIV, drinking days and binge drinking days were each associated with 
a reduction in primary care visit attendance after adjusting for age, race/ethnicity, education, 
domestic partner status, viral load, ART, depression, anxiety, and cocaine use. Moderate/severe 
anxiety and cocaine use were also independently associated with a reduction in visit attendance, 
irrespective of quantity or frequency of alcohol use. Depression, however, was not significantly 
associated with visit attendance in any model. These findings suggest that in this sample of 
predominantly middle-aged African American WHIV, frequency of alcohol use (binge drinking days 
and drinking days), age, cocaine use, and moderate/severe anxiety play a role in their RIC. Since RIC 
plays a key role in the HIV care continuum and ultimately affects PHIV’s health outcomes, the above 
91 
 
modifiable factors (alcohol use, cocaine use, and moderate/severe anxiety) that are negatively 
associated with RIC should be targeted for screening and treatment in the clinical setting. 
Our study found that among WHIV, frequency of alcohol use is negatively associated with 
RIC. This finding is consistent with prior studies with mixed samples of both men and women with 
HIV across various measures of RIC and alcohol use (Giordano et al., 2009; Giordano et al., 2005; 
Koirala et al., 2017; Monroe et al., 2016). In a study of 9,694 PHIV, heavy alcohol use was 
associated with worse IOM-defined retention, and daily/weekly binge drinking was associated with 
lower visit adherence (kept visits/ scheduled+ kept visits) (Monroe et al., 2016). Other studies of 
PHIV have used other measures to assess RIC such as at least one HIV care visit over 12 months 
(Koirala et al., 2017), and ≤6 months’ gap in care in the initial period (Giordano et al., 2005) and got 
consistent findings as our study. Importantly, our study not only reinforces findings of prior literature 
but also extends them to a sample of urban WHIV. Furthermore, in our study, we assessed RIC using 
missed visits rather than number of attended visits at defined intervals (or visit constancy) because 
the former could provide more prognostic information about a person’s health such as trend of 
change in CD4 count and plasma HIV level (Walburn, Swindells, Fisher, High, & Islam, 2012) and 
long-term mortality (Horberg et al., 2013; Mugavero et al., 2009) regardless of their retaining status 
defined by the IOM index and the DHHS indicator. 
Our study also finds that moderate/severe anxiety is negatively associated with RIC among 
WHIV. To date, there have been relatively few studies examining the effects of anxiety on RIC. In a 
qualitative study, researchers identified anxiety to be a barrier for PHIV to attend primary care visits 
(Tiruneh et al., 2016). This may relate to the fact that individuals with moderate/severe anxiety 
exhibit high levels of emotional, cognitive, and behavioral efforts to avoid or escape sources of 
distress (Hayes, Wilson, Gifford, Follette, & Strosahl, 1996). Those WHIV with moderate/severe 
anxiety may try to escape HIV-related events and thus were more likely to miss HIV primary care 
visits compared to those without moderate/severe anxiety. However, in another study of 136 PHIV in 
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South Africa, researchers found that anxiety is not associated with loss from care (not attending an 
appointment or receiving medications for three or more months or medical files removed) 
(Cichowitz, Maraba, Hamilton, Charalambous, & Hoffmann, 2017). However, in that study, 
researchers used a cut-off of 8 in the HADS-A score to define anxiety. Including mild cases as 
having anxiety may have washed out any effect. In addition, participants in that study consist of half 
men and women with HIV and measured RIC differently than our study.  
In addition, our study found that age is positively associated with RIC among this group of 
WHIV. This is consistent with previous research findings that advanced age is associated with better 
ART adherence among PHIV (Ettenhofer et al., 2009; Hinkin et al., 2004; Johnson, Heckman, 
Hansen, Kochman, & Sikkema, 2009; Newman et al., 2012). Our most robust finding that cocaine is 
negatively associated with RIC is consistent with findings of prior studies (Giordano et al., 2009; 
Hessol et al., 2009). The underlying mechanism may be that cocaine increases circulating dopamine 
levels in brain which controls pleasure and movement (National Institute on Drug Abuse) and thus 
lead to people’s behavioral changes such as mood swings, irritability, and paranoia (American 
Addiction Centers). This high level of disorganization makes WHIV less likely to attend scheduled 
primary care visits. In addition, we found that undetectable viral load was negatively associated with 
RIC. This is expected given the fact that undetectable viral load is a marker of good medication 
adherence (Haubrich et al., 1999; Kalichman et al., 2008) and thus satisfying RIC. 
Although some studies found that depressive symptoms are negatively associated with RIC 
(Cichowitz et al., 2017; Zuniga et al., 2016), our study did not find a significant association. This 
difference may be secondary to differences in definitions of retention [43] and sample characteristics 
[57], In addition, in contrast to other studies, we were able to adjust for anxiety symptoms and 
cocaine use, both of which are associated with depressive symptoms and RIC and may be 
unmeasured confounders in prior work of RIC. In a study of 433 newly diagnosed pregnant WHIV, 
researchers found that depression was not a predictor of lost to follow up in HIV care (Yotebieng, 
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Fokong, & Yotebieng, 2017). Further studies are needed to clarify this between depressive symptoms 
and RIC among WHIV, adjusting for potential confounders and using prospective methods.  
Although there is extensive literature demonstrating the negative relationship between alcohol 
use, mental health symptoms, and medication adherence (Magidson et al., 2017), there have been 
fewer studies examining RIC among PHIV, especially WHIV (Zuniga et al., 2016). Since RIC plays 
a key role in the HIV care continuum and ultimately affects patients’ outcomes, our study targeted a 
much-needed area. Our study yielded more in-depth evidence on the negative relationship between 
alcohol use and RIC by examining alcohol use with granular measures of use. It is important to look 
at alcohol use using different measures because their associated health risks often differ. For 
example, binge drinking is particularly harmful and is associated with over half of alcohol associated 
deaths in the US between 2002-2005 (Kanny et al., 2013).  
Another strength of our study is that the participants mainly consisted of middle-aged African 
American WHIV, most of whom completed a less than high school education, reported a low 
income, and lived alone. They are vulnerable in the context of living with HIV. A prior study found 
that African American WHIV experienced high levels of stigma and marginalization in health care 
that hindered their RIC (Sangaramoorthy, Jamison, & Dyer, 2017). In addition, for WHIV, alcohol 
use may further contribute to HIV-related health disparities after diagnosis (Myers et al., 2009), 
negatively affect their use of available HIV prevention and treatment resources (Hader, Smith, 
Moore, & Holmberg, 2001), and lead to negative social interactions (Myers et al., 2009).  
Despite the merits mentioned above, this study has some limitations. First, alcohol use was 
measured by self-reported timeline follow back method. While this method has been demonstrated to 
be reliable and widely used (Carpenter, Mayer, Fisher, Desai, & Durand, 1989), participants’ self-
report may underestimate their drinking. Indeed, the latest development in biomarkers, such as 
phosphatidylethanol (PEth) in blood, offers a more advanced method to assess the accuracy of self-
reported alcohol use (Monroe et al., 2016). Future studies using biomarkers in conjunction with 
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traditional self-report approaches may overcome measurement issues related to self-report. 
Moreover, in this study, we assessed baseline alcohol use using a 90-day TLFB and used 
retrospective clinical attendance for primary care visits. It is possible that this baseline alcohol use 
was not reflective of use over the prior 12 months. Future longitudinal prospective studies assessing 
this relationship are warranted. In addition, participants came from two parent studies, one being an 
RCT for a brief alcohol intervention. Thus, it is possible that WHIV who enrolled in the RCT were 
different from general WHIV and had more motivation to attend clinical visits. However, we have, to 
some extent, overcome this concern by only using retrospective visit data prior to their enrollment in 
the study. 
In summary, in this sample of WHIV, drinking days, binge drinking days, moderate/severe 
anxiety, and cocaine use were all negatively associated with primary care attendance. Given that 
missed appointments are associated with poor HIV treatment outcomes, it is important to identify 
these risk factors for missed appointments and provide resources and treatment that may improve 






















Note: SD=standard deviation. 
 
  
Variables Study population (n= 364) 
Age, years, mean (SD) 46.12 (8.11) 
African-American, n (%) 311 (85.4%) 
Education, mean (SD) 11.44 (2.03) 
Viral load and ART, n (%)   
Detectable viral load& no ART 71 (19.5%) 
Undetectable viral load regardless of 
ART 198 (54.4%) 
Detectable viral load & ART 95 (26.1%) 
Living without a partner, n (%) 319 (87.6%) 
Depressive symptoms, n (%)  
Minimal depression                                                               268 (73.6%)
Mild depression 46 (12.6%) 
Moderate depression 41 (11.3%) 
Severe depression 9 (2.5%) 
Anxiety, n (%)  
    Normal  222 (61.0%) 
    Mild 58 (15.9%) 
    Moderate/Severe 86 (23.6%) 
CD4 Cell Count (cells/mm3), mean (SD) 472.5 (309.1) 
Number of binge days, mean (SD) 10.25 (21.20) 
Number of drinking days, mean (SD) 13.35 (23.00) 
Number of drinks per drinking day, mean 
(SD) 4.43 (6.81) 
Use cocaine vs no use, n (%) 82 (22.5%) 
Number of scheduled visits, mean (SD) 8.47 (5.16) 
Number of attended visits, mean (SD) 5.41 (3.56) 
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Table 2 Logistic Mixed Models between drinks per drinking day (Model 1), binge drinking days (Model 2), and drinking days (Model 3), 
and primary care visits attendance 
Variables 
Model 1 (drinks per 
drinking day) 
Model 2 (binge drinking 
days) 
Model 3 (drinking days) 
OR (95% CI)        P value OR (95% CI) P value OR (95% CI) P value 
Age 1.02 (1.01-1.04) 0.01 1.02 (1.01--1.04) <.01 1.02 (1.01-1.04) 0.01 
African-American vs. others 1.05 (0.75-1.46) 0.80 1.04 (0.74-1.45) 0.83 1.05 (0.75-1.46) 0.78 
Education 1.02 (0.97-1.09) 0.42 1.02 (0.96-1.08) 0.48 1.02 (0.96-1.08) 0.46 
Viral load and ART        
Undetectable viral load 1.64 (1.20-2.26) <.01 1.61 (1.17-2.21) <.01 1.59 (1.15-2.18) <.01 
Detectable viral load& no ART 1.26 (0.89-1.77) 0.19 1.24 (0.88-1.74) 0.22 1.22 (0.87-1.71) 0.26 
Detectable viral load & ART Reference - Reference - Reference - 
Living with a partner vs. without a 
partner 
1.03 (0.73-1.46) 0.87 1.07 (0.76-1.51) 0.71 1.07 (0.76-1.51) 0.71 
Depressive symptoms       
Minimal depression                                                               Reference - Reference - Reference - 
Mild depression 1.41 (0.98-2.05) 0.07 1.42 (0.98-2.05) 0.06 1.42 (0.98-2.05) 0.06 
Moderate depression 1.43 (0.95-2.16) 0.08 1.49 (0.99-2.24) 0.06 1.50 (1.00-2.26) 0.05 
Severe depression 1.24 (0.53-2.90) 0.62 1.27 (0.55-2.98) 0.58 1.25 (0.54-2.92) 0.60 
Anxiety       
    Normal  Reference - Reference - Reference - 
    Mild 0.83 (0.60-1.15) 0.27 0.84 (0.61-1.16) 0.29 0.84 (0.61-1.16) 0.30 
    Moderate/Severe 0.69 (0.50-0.97) 0.03 0.69 (0.49-0.96) 0.03 0.69 (0.50-0.96) 0.03 
Number of binge drinking days - - 0.99 (0.99-1.00) 0.02 - - 
Number of drinking days - - - - 0.99 (0.99-1.00) 0.02 
Number of drinks per drinking day 0.99 (0.97-1.00) 0.08 - - - - 
Use cocaine vs. no use 0.57 (0.43-0.75) <.0001 0.57 (0.43-0.75) <.0001 0.57 (0.43-0.75) <.0001 
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Note: OR=Odds ratio, CI=confidence interval, SE=standard error. All analyses were conducted at a 0.05 
significance level. Adjusted for age, education, domestic partner status, cocaine use, race/ethnicity, anxiety, viral 
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Chapter 5: Summary and Conclusions 
Although we did not detect a relationship between change in anxiety and changes in alcohol 
use, we have other relevant findings that demonstrated the risks of cocaine use and depression on 
alcohol use among WHIV. Clinicians should assess depression status and cocaine use status for 
WHIV and provide them with resources and strategies to manage their depression and cocaine use. 
Clinicians should inform WHIV that if they increase cocaine or alcohol, they would possibly increase 
the use of the other substances and suffer from adverse outcomes associated with both substances. 
In addition, we found that drinking days, binge drinking days, moderate/severe anxiety, and 
cocaine use were all negatively associated with primary care attendance. Given that missed 
appointments are associated with poor HIV treatment outcomes, it is important to identify these risk 
factors for missed appointments and provide resources and treatment that may improve their 
appointment adherence and HIV treatment outcomes. 
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